

Review

# From Natural Products to New Synthetic Small Molecules: A Journey through the World of Xanthenes

Madalena M. M. Pinto <sup>1,2,\*</sup> , Andreia Palmeira <sup>1,2,†</sup>, Carla Fernandes <sup>1,2,†</sup> , Diana I. S. P. Resende <sup>1,2,†</sup> , Emília Sousa <sup>1,2,†</sup> , Honorina Cidade <sup>1,2,†</sup> , Maria Elizabeth Tiritan <sup>1,2,3,†</sup> , Marta Correia-da-Silva <sup>1,2,†</sup>  and Sara Cravo <sup>1,2,†</sup> 

- <sup>1</sup> Laboratory of Organic and Pharmaceutical Chemistry (LQOF), Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; andreiapalmeira@gmail.com (A.P.); cfernandes@ff.up.pt (C.F.); dresende@ff.up.pt (D.I.S.P.R.); esousa@ff.up.pt (E.S.); hcidade@ff.up.pt (H.C.); beth@ff.up.pt (M.E.T.); m\_correiasilva@ff.up.pt (M.C.-d.-S.); scravo@ff.up.pt (S.C.)
- <sup>2</sup> Interdisciplinary Centre of Marine and Environmental Research (CIIMAR), Terminal de Cruzeiros do Porto de Leixões, Av. General Norton de Matos s/n, 4450-208 Matosinhos, Portugal
- <sup>3</sup> CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra, 1317, 4585-116 Gandra PRD, Portugal
- \* Correspondence: madalena@ff.up.pt; Tel.: +351-966-092-514
- † These authors (by alphabetic order) contributed equally to this work.

**Abstract:** This work reviews the contributions of the corresponding author (M.M.M.P.) and her research group to Medicinal Chemistry concerning the isolation from plant and marine sources of xanthone derivatives as well as their synthesis, biological/pharmacological activities, formulation and analytical applications. Although her group activity has been spread over several chemical families with relevance in Medicinal Chemistry, the main focus of the investigation and research has been in the xanthone family. Xanthone derivatives have a variety of activities with great potential for therapeutic applications due to their versatile framework. The group has contributed with several libraries of xanthenes derivatives, with a variety of activities such as antitumor, anticoagulant, antiplatelet, anti-inflammatory, antimalarial, antimicrobial, hepatoprotective, antioxidant, and multidrug resistance reversal effects. Besides therapeutic applications, our group has also developed xanthone derivatives with analytical applications as chiral selectors for liquid chromatography and for maritime application as antifouling agents for marine paints. Chemically, it has been challenging to afford green chemistry methods and achieve enantiomeric purity of chiral derivatives. In this review, the structures of the most significant compounds will be presented.

**Keywords:** xanthenes; thioxanthenes; marine natural products; biological activities; synthesis; chiral



**Citation:** Pinto, M.M.M.; Palmeira, A.; Fernandes, C.; Resende, D.I.S.P.; Sousa, E.; Cidade, H.; Tiritan, M.E.; Correia-da-Silva, M.; Cravo, S. From Natural Products to New Synthetic Small Molecules: A Journey through the World of Xanthenes. *Molecules* **2021**, *26*, 431. <https://doi.org/10.3390/molecules26020431>

Academic Editor: Maria João Matos  
Received: 16 December 2020  
Accepted: 11 January 2021  
Published: 15 January 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

### 1.1. Why Choose “Xanthone Derivatives”?

#### 1.1.1. Xanthone: The Molecule

Xanthone is an aromatic oxygenated heterocyclic molecule, with a dibenzo- $\gamma$ -piron scaffold, known as 9*H*-xanthen-9-one, with the molecular formula of C<sub>13</sub>H<sub>8</sub>O<sub>2</sub> (Figure 1). The numbering and designation of rings A and B come from the biosynthetic pathways for the compounds from higher plants, A-ring (carbons 1–4) being acetate-derived whereas the shikimic acid pathway gives B-ring (carbons 5–8); the other carbon atoms are numbered according IUPAC 2004 recommendations for structure elucidation purposes.

X-Ray diffraction data are an important tool, not only for structure elucidation but also to help in understanding the mechanism of action of the wide range of biological and pharmacological activities showed by xanthone derivatives. The crystal structure of 9*H*-xanthen-9-one (Figure 1) was first reported in 1982 [1] and later, using more accurate

experimental techniques, the data have been improved [2,3]. Considering the molecule of xanthone itself in solid state, it is essentially planar due to the conjugated ring systems, except for the O(11) atom, which deviates 0.13 Å from the plane, with the central pyranoid ring with partial aromatic character. Due to the tricyclic-fused ring system, free rotation is limited. The rigidity of this scaffold contributes to the stability of the compound. For xanthone derivatives, slight differences can be found dependent on the nature of the substituents and their localization on the scaffold. The three-ring system can be slightly twisted along its longitudinal axis due to steric factors associated with the substituents, especially for bulky groups [3]. Chemically, the xanthone core looks very simple but can display a very rich reactivity profile, which results mainly from the resonance forms (Scheme 1). The oxygen atoms belonging to the biaryl ether group and the carbonyl group are involved in those forms; the planar tricyclic system, associated with a zwitterionic form, contributes for the poor solubility of the xanthone itself, which can be changed by adding substituents, concurring to higher solubility.





Figure 1. Structure of xanthone (9H-xanthen-9-one).




Scheme 1. Resonance forms of xanthone molecule.

#### 1.1.2. A New Molecule Was Born from the Lab and from the Nature


9H-Xanthen-9-one (Figure 1) is not a natural product, in fact, this structure was only obtained by synthesis in 1860, by Kolbe and Lautermann, using phosphorus oxychloride in sodium salicylate via condensation of phenol and salicylic acid [4]. Historically, the first natural xanthone described was gentisin (1,7-dihydroxy-3-methoxyxanthone) in 1821, isolated from the plant *Gentiana lutea* [5] and the first prenylxanthone derivative, tajixanthone, was isolated from the mycelium of *Aspergillus stellatus* in 1970 [6]. However, the first synthesis

proposed for a xanthone (hydroxyxanthone) was achieved by Michael, in 1883, and later by Kostanecki and Nessler, in 1891, through the distillation of *O*-hydroxy-benzoic acid, acetic anhydride and a phenol [7,8], or by heating phenyl salicylate alone [4,9] (Scheme 2), while the first total synthesis of a naturally occurring xanthone was described by Ullmann and Panchaud, in 1906, for euxanthone [10].



**Scheme 2.** Xanthone synthesis from phenyl salicylate proposed by Holleman and verified by Clarke [4,9].

The designation “xanthone” was coined by Schmid due to the yellow colour of the compound isolated from the pericarp of Mangosteen (*Garcinia mangostana* Linn.), a tropical fruit belonging to the Guttiferae family, which derives from the Greek word “xanthos” (yellow) (Figure 2) [11,12].



**Figure 2.** Structure of  $\alpha$ -mangostin and the yellow colour of the compound isolated from the *Garcinia mangostana* Linn.

Due to the great diversity of substituents, as well as the discovery and synthesis of new xanthenes, their classification by groups has evolved. Currently, they can be divided into six major groups: simple xanthenes, xanthone glycosides, prenylated xanthenes, xanthonolignoids, bisxanthenes, and miscellaneous xanthenes [13].

A large amount of research has been carried out, not only regarding isolation from terrestrial and marine sources, but also concerning compounds obtained by synthesis and with a large diversity of applications in medicinal, analytical and environmental chemistry. In 2005, one of us was Guest Editor of a Special issue of Current Medicinal Chemistry [14], which covered papers from isolation, synthesis, magnetic resonance spectroscopy and crystal X-ray studies of several xanthone derivatives to papers covering their biological activities and mechanisms of action [3,15–19].

### 1.1.3. Xanthone: A Privileged Scaffold

According to the concept of Evans et al. [20] the xanthone nucleus could be considered as a “privileged structure”, taking into account its binding to multiple, unrelated classes of protein receptors as high affinity ligands. Following, several authors associated the “xanthone” to the “privileged structure concept” [21–25]. This ability of xanthenes to interfere with a variety of biological targets is related with some special molecular features such as the presence of a heteroaromatic tricyclic ring system predominantly planar and rigid, a carbonyl group at the central ring able of several interactions, a biaryl ether group contributing to the electronic system, and the xanthone core that accommodates a vast variety of substituents at different positions.

## 2. A Library of Natural Mimetic Xanthenes Looking for Biological Diversity: From the Land and from the Sea

Our journey through the world of xanthenes comprises several stages and objectives. To obtain a library of natural mimetic xanthenes we have been working in an interactive

way including isolation of new compounds, total synthesis or molecular modifications, screening of biological activities and in-deep studies regarding their absorption, distribution, metabolism, excretion, toxicity (ADMET) properties as well as formulation of new compounds with appropriated drug delivery systems.

Natural xanthenes are secondary metabolites that may be found in higher plants, lichens and fungi from terrestrial and marine origins [13,26–31]. As a whole, we can say that the “meeting point” of our work is bioinspiration. The synthesis of non-natural nature-mimetic small molecules could be an opportunity of giving Nature a helping-hand in generating new bioactive agents and enlarging chemical-biological space. Following the idea of mimic Nature, a common approach of most medicinal chemistry programs it is crucial: (i) the choice of scaffolds, and (ii) the choice of strategies for molecular modifications. From our point of view, bioinspiration is very useful for selection of molecules and scaffolds as well as for selection of synthetic strategies.


Many products from marine origin have been described, and every year hundreds of new compounds are being discovered. The main sources of marine secondary metabolites with interest in medicinal chemistry are marine invertebrates such as sponges, tunicates, mollusks, and bryozoans, as well as algae and marine microorganisms, such as cyanobacteria and fungi. The designated “marine-derived fungi” must grow and sporulate in a marine environment, while facultative marine fungi are from terrestrial or freshwater habitats, but may also grow in the marine environment [32]. Considering that marine organisms are a very important source of new bioactive molecules with a plethora of biological activities with the antimicrobial being one of the most relevant for medicinal chemistry.

Xanthenes are not frequently mentioned as marine natural products due to the relatively late interest on marine microorganisms as providers of bioactive secondary metabolites comparing with terrestrial sources. For this reason, marine-derived fungi have emerged as a potential source of marine natural products and similar to their terrestrial counterparts, marine-derived fungi also produce xanthenes. Many xanthenes sharing the same structure can be found, for example, from both marine and terrestrial fungi while structures that are more complex have been found only in marine-derived fungi and actinomycetes. Comparing with other chemical families we can say that the number of xanthenes isolated from marine sources is quite scarce. Xanthenes were found predominantly in marine-derived fungi from the genera *Aspergillus*, *Penicillium*, *Monodictys*, *Emericella*, *Phoma*, *Paecilomyces*, *Chaetomium*, *Wardomyces* and from marine-derived *Actinomycetes* (*Actinomadura* and *Streptomyces*) [30]. From these data we can infer that the “marine xanthenes” obey the same rule as their terrestrial analogues concerning the large variety of biological activities, with greater emphasis on antimicrobial and antitumor activities. More recently, a review from our group (between 1989 and 2018) [27], emphasizes the anti-infective activity (antibacterial, antifungal, antiparasitic, and antiviral) of 53 xanthenes from the marine environment; furthermore, molecular descriptors, biophysicochemical properties, and pharmacokinetic parameters were calculated for three sets of compounds (xanthenes, hydroxyxanthenes, and glycosylated derivatives) and the chemical space occupied by marine xanthone derivatives was compared with marketed drugs. From our data it can be inferred that xanthone derivatives have a good compliance with the drug-likeness chemical space. Hydroxyxanthenes and glycosylated derivatives exceed the desired values and a poor pharmacokinetic behavior may be predicted [27].

Xanthenes with very different structures can be found in higher plants, lichens and bacteria, that have been reviewed since 1961 [33] until recently [13,15,23,34]. Figure 3 shows some representative xanthenes isolated by our group [35–40].

In this work, we describe xanthone derivatives divided in seven groups, based on different chemical families, concerning the diverse substituents. We will exemplify strategies that we consider significant for our contribution: prenylation, sulfation, and introduction of chiral moieties starting from simple oxygenated xanthenes. Given the objective of this work, most of the references indicated throughout the text correspond mainly to the contribution of our group to medicinal chemistry in the chemical family of xanthenes and not to

an exhaustive research in this area. We expect that this review may serve as an inspiration for other groups working with diverse “privileged structures” in an integrative way.



**Figure 3.** Terrestrial natural xanthenes isolated by our research group.


### 2.1. Simple Oxygenated Xanthenes

Simple oxygenated xanthenes are xanthenes with simple substituents such as hydroxyl, methoxy or methyl. This group is abundant in many natural products [15] and are starting points for many synthetic xanthenes [16]. As simple phenolic compounds, naturally-occurring simple oxygenated xanthenes have been described for their antioxidant properties that have been implicated in their hepatoprotective, anti-inflammatory, and cancer chemopreventive actions [18]. The influence of these substituents in the xanthone stability is important to understand the biological effects of these compounds [41]. Our group has been gathering physical-chemical-biological properties of these simple derivatives to use this information in drug design of more complex xanthenes.

Early in 1997, a small library of 12 mono and trioxxygenated xanthenes was investigated for their influence on the complement system and revealed anticomplementary activity of 3-hydroxy- and 4-hydroxyxanthenes [42], probably based on chelation of  $\text{Ca}^{2+}$ . This library of simple oxygenated xanthenes enlarged over the years both from natural [36,38,39] and synthetic derivatives, to more than 60 simple oxygenated xanthenes and hundreds of more complex derivatives with substituents at different positions. This collection of xanthenes allowed to establish structure-NMR chemical shift relationships [43] and gather X-ray crystallographic data [44,45] to guide synthetic chemists. Also, this appendance diversity-oriented synthesis allowed to develop a chemical toolbox of synthetic conditions and intermediates, based on classical and novel methods to obtain xanthenes, recently reviewed in [46] and to establish methods for their quantification validated in a diversity of matrices [47].

This chemical collection of pure xanthenes (>95%) was submitted to several screenings to discover their biological activities which allowed to build quantitative structure–activity relationship [(Q)SAR] models and to establish pharmacophores for antitumor [48], antioxidant [49], hepatoprotection [50], antifungal [29,51], antibacterial [52,53], antiobesity [54], antifouling [55] activities and/or targets such as monoaminoxidase (MAO) [56],

P-glycoprotein (P-gp) [57,58], protein kinase C (PKC) [59,60], tyrosinase [61], over these two last decades. Moreover, from these studies several simple oxygenated (Figure 4) or more complex hit compounds emerged that were additionally investigated in many directions, namely for further molecular modifications [62], for their cellular and molecular mechanism of actions [63,64], for their ADMET properties [65–67], for chromatographic applications [68,69] and for their incorporation in nanoformulations [70,71].



**Figure 4.** Hit compounds from simple oxygenated xanthenes for several activities and molecular targets.

The ethnopharmacological relevance of *Hypericum perforatum* extracts as antidepressant envisioned a first screening of simple oxygenated xanthenes on targets related to central nervous system (CNS) disorders. On MAO studies, among 53 simple natural and synthetic xanthenes, most of the compounds acted preferentially as MAO-A competitive, reversible inhibitors with  $IC_{50}$  values in the micro- to nanomolar range. Compound 1,5-dihydroxy-3-methoxyxanthone (1) with an  $IC_{50}$  of 40 nM for MAO-A emerged as the most active inhibitor. A surprising result was the strong activity and selectivity noted for the unsubstituted xanthone while hexasubstitution was an unfavourable feature for this effect. With this data, it was possible to build a 3D-QSAR model, which revealed the importance of the distance between two H-bond-acceptor groups in modulating this activity. Similar working hypothesis was made to investigate the hepatoprotective of xanthonolignoids (detailed in a following section), inspired in the hepatoprotective lignoid sylibin [50]. Along with xanthonolignoids, their synthetic intermediates were also investigated and 3,4-dihydroxy-2-methoxyxanthone and 2,3-dihydroxy-4-methoxyxanthone (2) were found to be even more potent than the investigated lignoids.

The tricyclic scaffold and the chemopreventive activity of naturally-occurring xanthenes were also the reason to investigate this collection of simple oxygenated xanthenes on antitumor screening activity. The *in vitro* effect of 27 xanthone derivatives on the growth of human cancer cell lines, led to select the naturally-occurring 1,3-dihydroxy-2-methylxanthone (3) that was further investigated in nanoparticle formulations to improve its activity [70]. One other hit that emerged from this study was 1,2-dihydroxyxanthone

(4), which was initially considered promising for its effect against melanoma [48]. Due to its catechol structure *peri* to carbonyl, this compound was the most promising antioxidant agent within this collection, that was further characterized for its chelating properties, its stability, phototoxicity, cytotoxic effect on a human keratinocyte cell line [49] and its modulatory effects on the activity of the THP-1 macrophage cell line, namely cytokine production [64]. The efficacy and safety profile of xanthone 4 with potential for skin care application deserves to be further explored. The investigation of tyrosinase as a molecular target, led to discover very recently, 1-methyl-3,4,6-trihydroxyxanthone (5) as a potent tyrosinase uncompetitive inhibitor [61] and to establish a QSAR model in which the partial negative surface area, the relative number of oxygen atoms, and the substitution pattern of the xanthonic core, were found to contribute to the tyrosinase inhibitory activity.

Similarly, for antiobesity activity, the number of rings, relative number of oxygen atoms, average structural information content, and partial negative surface area, among others, were positive descriptors for an increase of lipid reducing activity of xanthone derivatives [54]. In a screening of 85 polyphenols, 2,3-dimethoxyxanthone (6) was the hit compound showing strong lipid reducing activity in zebrafish larvae *in vivo* and with no general toxicity being found to reduce the mRNA expression of fatty acid synthase.

Insights into the molecular targets for antitumor activity revealed simple oxygenated xanthone as promising PKC modulators, using an *in vivo* yeast phenotypic assay. Methoxylated xanthone derivatives were found to be promising PKC activators showing high selectivity for individual PKC isoforms, proving their utility for a detailed study of the physiological and pathophysiological roles of PKC isoforms [59]. In contrast, simple oxygenated xanthonones, with an aldehyde in position C-1, were found to be potent inhibitors of PKC [60,63]. This result led us to explore this type of substituent in simple oxygenated xanthonones and to discover the inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma, 1-carbaldehyde-3,4-dimethoxyxanthone (7). This xanthone was able to release TAp73 from its interaction with both MDM2 and mutant p53, enhancing TAp73 transcriptional activity, cell cycle arrest, and apoptosis in p53-null and mutant p53-expressing tumor cells [63]. Putative metabolites with 1-(hydroxymethyl)- or carboxylic acid at position C-1 were inactive and since this compound was found to be a TAp73 activator, we investigated its antitumor potential towards neuroblastoma, discovering its potent effect in patient-derived neuroblastoma cells, both alone and in combination with conventional chemotherapeutics [63]. Very recently, xanthone 7 was encapsulated in nanostructured lipid carriers (NLCs) by ultrasonication, obtaining final loaded NLCs with mean particle sizes suitable for topical application and high encapsulation efficiencies. These loaded formulations seemed to be more cytotoxic against melanoma A375 cell line than unloaded NLCs, which indicates the potential use of NLCs as a carrier for this TAp73 activator with potent antiproliferative effect on melanoma A375 cell lines, improving its efficacy [72].

As mentioned, while performing biological activity studies, several drug-like properties (physico-chemical parameters, stability, photostability, intestinal permeability, albumin binding, toxicity, etc.) were simultaneously investigated [66,73]. While showing favourable permeability parameters, the ability of dihydroxylated xanthonones for P-gp activation was disclosed with 3,6-dihydroxyxanthone (8) being the most active. Further studies pointed their putative application as antidotes of paraquat, by protection against the cytotoxicity induced by this pesticide P-gp substrate [57,58,74].

Beyond pharmacological applications, the antifouling (AF) activity of this collection of simple oxygenated xanthonones was tested following our previous results concerning the AF activity of a sulfated and glycosylated xanthone (Section 2.4). This screening highlighted 3,4-dihydroxyxanthone (9) among this collection with *in vivo* activity toward the settlement of *Mytilus galloprovincialis* larvae ( $EC_{50} = 11.53 \mu\text{M}$ ) and low toxicity to this macrofouling species ( $LC_{50} > 500 \mu\text{M}$  and  $LC_{50}/EC_{50} = 43$ ) and to a non-fouling species, the brine shrimp *Artemia salina* (<10% mortality at  $50 \mu\text{M}$ ). Xanthone 9 induced alterations in


the mussel plantigrade larvae proteome, particularly toward the functions of cytoskeleton, chaperone-mediated regulation of protein activity, and cell redox status [55].

Finally, as antimicrobial agents or adjuvants, simple oxygenated xanthenes are inactive or less active than other derivatives with halogens and amine substituents [29,51,53]. These studies will be detailed in following sections.

Overall, most of the discovered hits were trioxygenated derivatives (Figure 4), mainly with antitumor activity. Dihydroxyxanthenes, particularly those with a catechol moiety, were found to be the most promising hits for activities in which redox mechanisms are involved. From a medicinal chemistry perspective, these catechol hits could be considered as PAINS, pan-assay interference compounds [75]. Although their activity does not depend on a specific, drug-like interaction between the molecule and a protein, they are able to coat a protein or sequester metal ions that are essential to a protein's function, and these are mechanisms recognized for some FDA approved-drugs. Moreover, a screening hit compound is useful when supported by strong SAR complemented by hit-to-lead optimization [76], that we will further explore in the next sections. In fact, these simple xanthenes derivatives were starting points to increase complexity and lipophilicity allowing hit optimization.

## 2.2. Prenylated Xanthenes

Prenylated xanthenes are the major group of naturally occurring xanthenes. The majority of reported synthetic prenylated xanthenes possess a 3-methylbut-2-enyl or isoprenyl group (A, Figure 5). Nevertheless, the presence of other open chain prenyl groups can also be found in literature; compounds containing 2,2-dimethyldihydropyran (B), 2,2-dimethylpyran (C) and 2,3,3-trimethyldihydrofuran (D) groups, which are the result of cyclization of the prenyl substituents with the *ortho* hydroxyl group could also be found (Figure 5) [77]. Among these substitution patterns, our group has been involved in the synthesis of bioactive prenylxanthenes with isoprenyl (A), 2,2-dimethyldihydropyran (B), 2,2-dimethylpyran (C), 2,3,3-trimethyldihydrofuran (D), 1,1-dimethylallyl (E), and 3-methylbut-3-en-2-yl (F) and groups (Figure 5).




**Figure 5.** Prenyl groups found in prenylated xanthenes reported by our group.

Xanthenes with open chain prenyl groups, as well as dihydropyranoxanthenes and pyranoxanthenes, were firstly obtained by our group through classical synthetic methodologies. Prenylation was carried out from hydroxyxanthenes by a nucleophilic substitution reaction. Dihydropyranoxanthenes were synthesized by cyclization of mono-oxyprenylated xanthenes, while the synthesis of pyranoxanthenes was achieved by dehydrogenation of dihydropyranoxanthenes or using a benzopyran derivative as building block (Scheme 3).

Following, our group used “non-classical” methodologies, namely microwave-assisted organic synthesis (MAOS) and heterogeneous catalysis, to optimize the synthetic approach to obtain this group of xanthenes. It was also applied the combined method of heterogeneous catalysis with MW irradiation [78–81]. MW methodology was applied for the first time to the synthesis of these derivatives, being obtained several prenylated xanthenes with better yields, lower reaction times and higher selectivity when compared to conventional synthesis [78–81]. Heterogeneous catalysis methodology was also used for the first time, in the synthesis of dihydropyranoxanthenes. By this method, dihydropyranoxanthenes

were obtained from hydroxyxanthenes, through a one-pot synthesis, in the presence of montmorillonite K10 clay as solid catalyst. The coupling of heterogeneous catalysis with MW irradiation provided a chemical process with several advantages when compared to classical methods, such as enhanced reaction rates, better yields and selectivity to obtain xanthenes with an extra dihydropyran ring [79].




**Scheme 3.** Examples of the main synthetic approaches to obtain prenylated xanthenes using classical and “non-classical” methodologies, reported by our group.

The presence of prenyl groups in the xanthone nucleus can influence the physico-chemical properties, namely lipophilicity. Additionally, these groups also have impact in the biological activity, as they affect the three-dimensional properties of the xanthone and consequently the interaction with the biological targets [82]. In fact, a relationship between activity and the presence of prenyl groups in key-positions on the xanthone nucleus was associated with some biological activities, such as antitumor, anti-inflammatory and human lymphocyte proliferation inhibitory effects [34,38,83].

The synthesis of a library of prenylated xanthenes was shown to be fruitful with many of the synthesized compounds presenting encouraging antitumor activity in different cell lines. The first research work of our group concerning the synthesis of bioactive prenylated xanthenes, comprised the synthesis of a small library of *O*-prenylated xanthenes using 1,3-dihydroxy-2-methylxanthone (**3**, Figure 4) as building block, previously identified by us as a promising *in vitro* growth inhibitor of human tumor cell lines [48], as well as the

*nor*-derivative 1,3-dihydroxyxanthone (**10**, Figure 6) [84]. Among synthesized compounds, xanthenes **14** and **15** with isoprenyl and 1,1-dimethylallyl groups and xanthone **11** with a 2,2-dimethyldihydropyran group, showed improved in vitro growth inhibitory activity against the breast cancer MCF-7 cell line, if compared with their parent compounds **3** and **10**, while the growth inhibitory activity against the other cell lines was lost, suggesting some selectivity to MCF-7 cells [84].




**Figure 6.** Synthetic prenylated xanthenes with promising in vitro growth inhibitory effect in human tumor cell lines identified by our group, reported in [84,85].

In 2009, a rigidification strategy aiming to improve the antitumor activity of previously synthesized dihydropyranoxanthone derivative **13** was applied by our group and pyranoxanthenes **16–18** were obtained by unsaturation strategy applied to the dihydropyran ring of dihydropyranoxanthenes **11–13**, respectively (Figure 6) [85]. Moreover, two new *C*-prenylated derivatives (**20** and **21**) were synthesized by prenylation of xanthone **19** (Figure 6). Interestingly, when comparing the effects of the pyranoxanthenes **16–18** on the growth of MCF-7 cells with those of their respective dihydropyran xanthenes used as building blocks **11–13**, it was found that the presence of the unsaturation in the pyran ring was associated with loss of inhibitory activity against MCF-7, suggesting that the rigidification failed to give an improvement of activity. However, *C*-prenylation of the inactive xanthone **19** was associated with the appearance of some growth inhibitory effect against MCF-7 of derivatives **20** and **21** [85].

Aiming to pursue the study of the influence of prenylation in the antitumor activity of xanthenes, in 2010 the synthesis of both open-chain and fused prenylated derivatives of 3,4-dihydroxyxanthone (**9**, Figure 4) was accomplished [86]. All the synthesized compounds reduced cell viability of K-562 cell line, derived from a blastic phase of human chronic myelogenous leukemia, using a trypan blue exclusion assay, being 12-hydroxy-2,2-dimethyl-3,4-dihydro-2*H*,6*H*-pyrano [3,2-*b*]xanthen-6-one (**22**, Figure 7) the most potent compound. Additionally, **22** decreased cellular proliferation, induced S-phase cell cycle

arrest and apoptosis, being this effect associated with an increase of cleaved PARP and Bid, as well as a decrease in Bcl-xL in K-562 cells. Further studies in K-562 leukemia cells also revealed that **22** can act as a non-competitive P-gp inhibitor, pointing out its potential to act in MDR cancer cells [66]. Additionally, **22** showed promising in vitro growth inhibitory effect in estrogen-dependent ER (+) MCF-7 (breast) cells [87]. Interestingly, an enhancement in the antiestrogenic effect of 4-hydroxytamoxifen was also observed in ER (+) MCF-7 cells treated with the xanthone **22** [87]. Considering that the pyranoxanthone **22** was shown to exhibit potent antiproliferative activity in leukemia [86] and breast cell lines [86,87], this hit compound was selected for further investigation concerning the mechanism of action at a molecular level and the optimization of potency through chemical and nanotechnology approaches.



**Figure 7.** Xanthones with improved growth inhibitory activity against MCF-7, NCI-H460, A375-C5 and HL-60 cell lines reported in [78,80].


Considering the disclosed mechanism elucidation for naturally occurring prenylated xanthone  $\alpha$ -mangostin and gambogic acid as inhibitors of MDM2-p53 interaction by some of us [88] and the promising growth inhibitory activity of **22** in cancer cell lines [86,87], this pyranoxanthone as well as other structure related compounds were submitted to in silico and in vitro studies in order to explore their potential as novel MDM2-p53 inhibitors. The p53 tumor suppressor is a major transcription factor with a crucial role in cell proliferation and death. The activity of p53 is commonly lost in cancers either by mutation in the TP53 gene, or by inactivation due to the overexpression of the main endogenous negative regulator, murine double minute 2 (MDM2). Therefore, restoration of p53 activity by inhibiting the MDM2-p53 interaction represents an appealing therapeutic strategy for many wild-type p53 tumors with overexpressed MDM2 [89]. Compound **22** was in fact identified as a putative inhibitor of MDM2-p53 interaction using a yeast phenotypic assay for the screening of inhibitors of MDM2-p53 interaction in association with a yeast p53 transactivation assay [90]. The activity of **22** as inhibitor of MDM2-p53 interaction was further validated in human tumor cells expressing wild-type p53 and overexpressed MDM2. Remarkably, **22** mimicked the activity of known p53 activators, leading to p53 stabilization and activation of p53-dependent transcriptional activity. In addition, it increased p21 and Bax protein levels, and caspase-7 cleavage. Computational docking studies allowed predicting that, like nutlin-3a, a known small-molecule inhibitor of MDM2-p53 interaction, **22** binds to the p53-binding site of MDM2. With this research line, a novel small-molecule inhibitor of MDM2-p53 interaction with a xanthone scaffold was identified for the first time, which could be used as molecular probe [90] and inspired other researchers to develop new anticancer agents targeting p53 [91]. Nevertheless, using adequate software (ACD/Labs software, Toronto, Canada) the calculated maximum water solubility of **22** was only 16  $\mu\text{g}/\text{mL}$  [92]. This poor aqueous solubility could be a major drawback for its potential use in therapy. Therefore, drug delivery systems, including nanosphere, nanocapsule and nanoparticle formulations were developed [92,93]. Among

these, nanocapsules containing poly(D,L-lactide-co-glycolide) (PLGA), polyvinyl alcohol (PVA) and Mygliol<sup>®</sup> 812 were found to be noncytotoxic to MCF-7 cell line and **22**-loaded nanocapsules with an incorporation efficiency of 77% revealed to be more potent than the free compound against cell growth inhibition, which may be related to the enhancement in its intracellular delivery [90]. These results suggest that it was possible to enhance the effect of the hit compound **22** through the development of suitable noncytotoxic polymeric nanoparticles. In addition to nanotechnological approaches to optimize **22** previously described, our group has also been involved in the optimization of the potency of this xanthone through a chemical approach. Therefore, **22** was used as the starting point in the search for more potent antitumor agents. To increase the probability of success, the pharmacokinetic behaviour was also considered in this research plan. Accordingly, it was decided to optimize this compound following a multidimensional approach regarding, in parallel, at the activity and physicochemical properties, with the latter being used as a tool to predict the pharmacokinetic behaviour.

A first series of 17 analogues of **22** with a linear tetracyclic system and different substituents in ring A were synthesized and evaluated for their antiproliferative activity against MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), A375-C5 (melanoma) and HL-60 (acute myeloid leukemia) cell lines. A new route, through a benzophenone intermediate was developed for the synthesis of **22** and its 17 analogues bearing different substituents on ring A and different ring D orientation. Some of the newly synthesized compounds (**23–26**) were more active than **22** in the four tumor cell lines tested (Figure 7). Particularly, analogue **24** with an 8-diethylamino group at A ring and a 2,2-dimethyl-3,4-dihydropyrano ring linked to the B ring of xanthone nucleus showed to be the most active in all tested cell lines. In general, like **22**, all synthesized analogues were more active towards the HL-60 tumor cell line, with the most potent compound (**23**) having a GI<sub>50</sub> of 5.14 µM, lower than the hit compound **22** (GI<sub>50</sub> of 23.41 µM). Interestingly, all compounds showed a logK<sub>p</sub> between 3 and 5 in two membrane models, namely liposomes and micelles, and all tested compounds showed low solubility, being this explained by their high rigidity and planarity [80]. Overall results allowed concluding some considerations concerning structure-activity and structure-solubility relationships, which are highlighted in Scheme 4.

A second series of 20 analogues of **22** with linear and angular fused pyran and dihydropyran rings were also synthesized and evaluated for their lipophilicity and antiproliferative activity in human tumor cell lines in order to perform SAR studies concerning the effect of the fused ring orientation and oxygenation pattern in pyranoxanthenes (Scheme 4) [78]. The compounds were synthesized either by molecular modification of simple oxygenated xanthenes or by total synthesis through benzophenone and diaryl ether routes. The introduction of pyran rings in simple oxygenated xanthenes were accomplished either by the cyclization with platinum of the dimethylpropargyl aryl ethers, or by the condensation with prenal or by the reaction with prenyl bromide catalysed by Montmorillonite K-10 and MW heating. The total synthesis of pyranoxanthenes was carried out via diaryl ether and benzophenone using the appropriate benzopyrans and carboxylic acid derivatives as building blocks. From this work, the angular pyranoxanthone **27** (Figure 7) emerged as the most potent cell growth inhibitor of tested human tumor cell lines ( $3.2 < \text{GI}_{50} < 13.3$  µM), showing suitable drug-like lipophilicity. Overall results obtained for the evaluation of the cell growth inhibitory activity in the referred four tumor cell lines allowed to advance some putative SAR summarized in Scheme 4.

In 2020, to further explore the mode of action of **22** in cells, as well as other structure related(thio)xanthenes with antitumor activity, the transcriptional response of the filamentous fungus *Neurospora crassa* to these compounds using high throughput RNA sequencing was evaluated. These compounds showed to induce genes which express ABC transporters in *N. crassa*, particularly *atrB* and *cdr4*, and to repress genes that are evocative of genes downregulated during oxidative stress [94].



**Scheme 4.** Putative SAR and structure–solubility relationship considerations for the analogues of **22** reported in [78,80] (IEGCL: inhibitory effect in growth of tumor cell lines).


Although the antitumor activity of prenylated xanthenes was the most reported biological activity, the potential of these compounds as AF agents has recently been explored by our group. In this context, and as a part of our efforts to discover innovative antifoulants inspired in natural products, xanthone **22** was also investigated along with the simple oxygenated xanthenes (Section 2.1). This prenylated xanthone **22** showed even more potent in vivo activity toward the settlement of *Mytilus galloprovincialis* larvae ( $EC_{50} = 4.60 \mu\text{M}$ ) than the dihydroxyxanthone **9**, showing also a low toxicity profile to this macrofouling species ( $LC_{50} > 500 \mu\text{M}$  and  $LC_{50}/EC_{50} > 108.70$ ) and to *Artemia salina* (<10% mortality at  $50 \mu\text{M}$ ). Concerning the mechanisms of action in mussel larvae, xanthone **22** showed a specific target directly related with the proximal thread proteins (TMPs), which are expressed by bivalve molluscs that adhere to underwater surfaces through the production of byssal threads [55].

To sum up, 50 new prenylated xanthenes were synthesized by our group using classical and non-classical methodologies. Notably, MAOS and the combination of heterogeneous catalysis (K10 clay) with MW irradiation were described for the first time for the synthesis of prenylated xanthenes. The majority of prenylated derivatives were studied for their in vitro growth inhibitory activity against tumor cell lines. The pyranoxanthone **22** emerged as the most promising in vitro growth inhibitor, being this effect associated mostly with a MDM2-p53 inhibitory effect. Nevertheless, other 26 compounds had also good outcomes against tumor cell lines; the results obtained allowed us to establish structure-activity and structure-solubility relationship considerations which will allow in the future the design of new prenylated xanthenes with improved antitumor activity.

### 2.3. Halogenated and Carboxyxanthenes

Over the preceding decade, more than 100 xanthenes from lichen sources were identified [95], but only a limited number have been investigated for their bioactivities [31]. Particularly, chlorinated lichen xanthenes have been found attractive for their antibacterial and antifungal activities [96]. Based on these models, a series of novel chlorinated

xanthenes with different substitution patterns were prepared and evaluated for its antimicrobial activity potential [29]. The presence of chlorine at C-3 seems to have some influence on the antibacterial activity since 3-chloro-4,6-dimethoxy-1-methyl-9*H*-xanthen-9-one (**28**) showed promising antibacterial activity against *E. faecalis* (ATCC 29212) and *S. aureus* ATCC 29,213 (Figure 8). On the other hand, 2,7-dichloro-3,4,6-trimethoxy-1-methyl-9*H*-xanthen-9-one (**29**), with chlorine atoms at C-2 and C-7, exhibited potent antifungal activity suggesting that their joint presence may be required for this effect, similarly to the natural xanthone, thiophanic acid. Inspired by these results and in order to further extend the diversity of the library, our group also explored the potential of brominated xanthenes as antimicrobial agents [53]. Although no antifungal activity was observed for the tested compounds, 1-(dibromomethyl)-3,4-dimethoxy-9*H*-xanthen-9-one (**30**) and 1-(dibromomethyl)-3,4,6-trimethoxy-9*H*-xanthen-9-one (**31**) exhibited antibacterial activity against all seven bacterial (including two multidrug-resistant) tested strains (Figure 8). While the studied xanthenes exhibited great potential as antibacterial (**28**, **30** and **31**) or antifungal (**29**) agents, the low solubility displayed by some derivatives limited further screenings. Nevertheless, these can be used in the future as models to improve drug-like properties. In the scope of the same study, other xanthone derivatives modified at C-1 (CH<sub>3</sub>, CHO, COOH, COOCH<sub>3</sub>, or NOH) were also synthesized and screened for their antimicrobial activity. However, none of the tested compounds showed relevant activity against the five fungal and seven bacterial (including two multidrug-resistant) strains tested.



**Figure 8.** Antimicrobial halogenated xanthenes **28–33**.

In a study involving the synthesis of dimers of xanthenes as bis-intercalators [97], bromohexyloxanthones **34–36** were obtained as side products and were investigated for their effect on the *in vitro* growth of human tumor cell lines (Figure 9). Although for bromoalkoxyxanthone **35** no relevant growth inhibition was observed on all the tested tumor cell lines, the bromoalkoxyxanthenes **34** and **36** showed an interesting growth inhibitory effect, higher than the parent hydroxylated xanthenes and the target bisxanthenes. Although more studies are needed to establish a SAR, results showed that one free hydroxyl group in the bromoalkoxyxanthone scaffold **35** is unfavourable to the growth inhibitory activity. Additionally, X-ray crystallography allowed the structure elucidation of 1-(6-bromohexyloxy)-xanthone (**34**) which can be helpful in the future to disclose some mechanistic aspects concerning the binding of **34** to DNA or other putative targets.

Yicathins B and C are two marine natural xanthenes that have shown antibacterial and antifungal activities [98]. The total synthesis of yicathin B (**37**) and yicathin C (**38**), along with six analogues (**39–44**) was reported by our group (Figure 10) [73]. Lipophilicity of yicathins and their analogues was evaluated using *in silico* and experimental biomimetic methodologies. The obtained partition coefficients were quite different, namely for ionized compounds at physiological pH. Nevertheless, the lipophilicity of the synthesized compounds were within the limits preconized by the most common “drug-like” guidelines.

In vitro antitumor and anti-inflammatory activities were evaluated. Antitumor activity was screened in three human tumor cell lines, but the compounds did not reveal a significant ability to inhibit cell growth, being 48.70  $\mu\text{M}$  the lowest  $\text{GI}_{50}$  value. Nevertheless, compounds **37**, **41**, and **43** showed a significant in vitro anti-inflammatory activity, which was comparable with well-known nonsteroidal anti-inflammatory drugs (NSAIDs), like diclofenac and celecoxib.




Figure 9. Bromohexyloxyxanthenones **34–36**.




Figure 10. Structure of yicathin B (**37**) and yicathin C (**38**) and their six analogues **39–44**.

#### 2.4. Aminated Xanthenes

Our group performed a complete SAR study through the analysis of various xanthone derivatives with multitarget activity against Alzheimer Disease (AD) [99]. It was found that the presence of a methoxy group at C-3 increased the inhibition of MAO as well as the inhibition of acetylcholinesterase (AChE) and the presence of a hydroxyl group on the xanthone scaffold was important for antioxidant activity. Based on this study and considering the potential of tricyclic amine drugs for CNS diseases, our group designed and prepared several xanthone derivatives to be used as dual agents for AD with AChE inhibitory and antioxidant activities [100]. Aminated xanthone **45** was obtained from 1,8-dihydroxy-3-methoxy-9*H*-xanthen-9-one by Mannich reaction with formaldehyde and dimethylamine (Figure 11), while xanthenes **46–51** were obtained by reductive amination from the corresponding carbaldehydes (Figure 11), previously obtained from oxygenated xanthenes by a Duff formylation. From this study, xanthone **45** emerged as a hit compound exhibiting interesting dual AChE inhibitory effect and antioxidant activity (ferrous and copper ions chelating properties).

Another example of hybridization approach was also explored by us regarding the potential of aminated xanthenes to disrupt the MDM2-p53 interaction using a yeast cell-based assay [101]. Previous studies developed by our group disclosed two xanthone derivatives, pyranoxanthone **22** (Figure 7) and 1-carbaldehyde-3,4-dimethoxyxanthone **7** (Figure 4) as MDM2-p53/TAp73 inhibitors. Hence, xanthone **7** was used as starting material for the synthesis of a series of eleven aminated xanthenes via reductive amina-

tion. From this study, xanthone **52** (Figure 12) was identified as a putative p53-activating agent, inhibiting the growth of human colon adenocarcinoma HCT116 cell line, being this effect associated with cell cycle arrest through activation of the p53 pathway. Although further studies are required to confirm the mechanism of action of **52**, these results demonstrated the potential usefulness of coupling amine-containing structural motifs of known MDM2-p53 disruptors into the 3,4-dioxygenated xanthone scaffold, which may lead to the identification of a novel xanthone derivative with promising antitumor activity.




Figure 11. Aminated xanthones 45–51.





Figure 12. Aminated xanthones 52–55.

Later, another series of eleven aminated xanthones, together with xanthone **7** (Figure 4), 1-(hydroxymethyl)-3,4-dimethoxy-9*H*-xanthen-9-one and the aminated xanthone **52** previously studied for their ability to disrupt the MDM2-p53 interaction, were also screened for their antimicrobial activity against five fungal and seven bacterial (including two multidrug-resistant) strains [53]. The results of antimicrobial screening revealed the potential of compounds with halogen atoms as the most promising in terms of antibacterial activity, with some of the representatives (**53**, **54** and **55**) being highly active against either Gram-positive or Gram-negative strains. Regarding to antifungal activity, compound **54**

revealed a potent inhibitory effect on the growth of dermatophyte clinical strains (*T. rubrum* FF5, *M. canis* FF1 and *E. floccosum* FF9). The fungicidal activity was observed for compound **55** with *T. rubrum* FF5. Also, **54** showed a potent inhibitory effect of *C. albicans* ATCC 10,231 germ tube and biofilm formation, important virulence factors. Due to low solubility, conversion to the corresponding hydrochloride salts increased the potential of the studied aminated xanthenes as antibacterial or antifungal agents [53].

Hydroxylated xanthenes have previously revealed to have antimalarial activity, pointing to the same molecular mechanism as antimalarial 4-aminoquinolines mefloquine, halofantrine, and quinine. [102] This mechanism consists in preventing the process of haemozoin formation; hence, the consequent concentration of free haematin would be sufficient to kill the parasite [102]. These compounds might interact with haematin in the form of a  $\mu$ -oxo dimer or a dimer of haemozoin. This interaction would lead to stabilization of haematin in a soluble form, consequently leading to parasite death [103]. Aided by docking simulations [103], our group designed a series of twelve new chlorinated 9*H*-xanthenes with a [2-(diethylamino)ethyl]amino group in position C-1 and one to four Cl-atoms in different positions (Figure 13), and studied their antimalarial activities [104,105]. All twelve compounds were found to be active against the chloroquine-susceptible and chloroquine-resistant strains 3D7 and Dd2, respectively, of *Plasmodium falciparum*. A more pronounced effect was observed for strain 3D7 ( $IC_{50}$  = 1.7–18.1  $\mu$ M) relative to strain Dd2 ( $IC_{50}$  = 3.9–66.4  $\mu$ M). From this study, compound **56** (Figure 13) emerged as a hit compound due to significant in vitro activity ( $IC_{50}$  = 3.9  $\mu$ M) towards the resistant Dd2 strain. The position and number of the Cl substituents are of great importance regarding activity. When compared to known antimalarial drugs, a Cl atom in position C-6 seems to be important for activity in both strains, as well as a single Cl atom in position C-5, indicating a similar mechanism of action.




**Figure 13.** Structures of known antimalarial drugs based on chlorinated 4-aminoquinolines and putative SAR analysis of aminated xanthenes and hit compound **56**.

Due to their versatility, aminated xanthenes have been widely studied over the last years by our research group. The main limitation of these compounds is their low solubility in water, which was easily overcome through the conversion into hydrochlorides. The

synthesis of hydrochloride salts also enhanced their activity (which was validated in the antimicrobial screening).

### 2.5. Sulfated and/or Glycosylated Xanthenes

Heparin polysaccharide is decorated by numerous ionic groups, via sulfate and carboxylate groups. Since heparin has an average molecular weight of 15 kDa, this property gives heparin the highest negative charge density of any known naturally derived biomolecule. Although heparin has been one of the most effective and widely used drugs of the past century [106], it is beset with many complications including haemorrhage, thrombocytopenia, osteoporosis and inconsistent patient response, owing to its polyanionic, polymeric and polydisperse nature. Functional mimics of heparin without its adverse effects are highly desirable as an alternative for anticoagulant therapy [107]. Replacing the sulfate groups in the binding domain of heparin with other anions nullifies its anticoagulant activity. Therefore, sulfated small molecules are expected to preserve some molecular properties of heparin but with reduced anionic character, higher hydrophobic nature, and feasible synthesis (Figure 14A).




**Figure 14.** Sulfated and glycosylated xanthenes (XGS) as mimetics of several physiologic processes: (A). Anticoagulant effects as mimetics of heparin, (B). Antiviral effects as mimetics of GAGs; (C). Antifouling effects as mimetics of marine antifouling sulfated metabolites. HBD: heparin binding domain; GAG: glycosaminoglycan.

In this direction, two polysulfated derivatives of the naturally occurring glycosylated xanthone, mangiferin, were prepared by our group (57 and 58, Figure 15) to study their anticoagulant effects [108].

Mangiferin was selected for sulfation as part of our top priority of developing new molecules derived by molecular modifications of known drugs, for several reasons as follows. Modification of molecules that have already been used in human therapy leads to compounds with more predictable and less complex pharmacokinetics, lower incidence of side effects, and less demanding clinical studies. The wide use of mangiferin by humans for many years suggests low toxicity not only for mangiferin but also for their metabolites and analogues. Protective effects of mangiferin with regard to cardio, renal, liver, and brain toxicity are well documented [109]. Because aryl C-glycosides are stable analogues of O-glycosides, resistant to metabolic processes, the C-glycoside mangiferin emerged as an interesting derivative to be sulfated. Starting from commercial mangiferin, sulfation was performed with triethylamine sulfur trioxide adduct in dimethylacetamide at 65 °C for 24 h. Depending on the loading of sulfur trioxide adduct, mangiferin tetrasulfate (57) and mangiferin heptasulfate (58) were obtained [108]. Due to the sulfate groups, 57 and 58 revealed a better solubility in water than mangiferin. Both derivatives exhibited antico-

agulant activity when tested *in vitro* in human plasma, with the heptasulfate mangiferin (**58**) being more potent. Enzymatic *in vitro* assays to elucidate coagulation targets of **58** demonstrated that this sulfated mangiferin was a selective direct inhibitor of factor Xa. This work inspired Q. Rashid et al. to explore by *in silico* studies the binding mode of several sulfated and non-sulfated xanthenes on coagulation proteases [110].



**Figure 15.** Sulfated and/or glycosylated bioactive xanthenes.

A xanthone *O*-glycosylated on both rings (**59**, Figure 15) was also planned to interact in an extended binding area of proteins of the coagulation process [111]. According to this hypothesis, the sulfated diglycosylxanthone would lead to a molecule with higher molecular size and number of sulfate groups than the previous polysulfated mangiferin derivatives and thus increase anticoagulant effects. As planned, this octasulfated xanthone was more potent than the tetra and heptasulfated mangiferins and was shown to activate coagulation by a dual mechanism, inhibiting the factor Xa directly and via antithrombin III activation [108].

In addition to anticoagulant effect, xanthonosides **58** and **59** were also endowed with antiplatelet effects. Their antiplatelet activity was attributed to the inhibition of arachidonic acid and ADP-induced platelet aggregation [108]. The dual antiaggregant behaviour of these small sulfated molecules affords an opportunity to discover different molecules from the known antiplatelet agents with possibly different pharmacological profile. Dual antiplatelet therapy with acetyl salicylic acid (inhibitor of arachidonic acid-induced platelet aggregation) and a thienopyridine (inhibitor of ADP-induced platelet aggregation) is often recommended for high-risk patients. On the other hand, molecules such as xanthenes **58** and **59**, which simultaneously target the antiplatelet and anticoagulant pathways, could be useful to prevent and treat both venous and arterial thrombosis. In the past decade, dual anticoagulant/antiplatelet agents have been persuaded, although such dual agents have not yet achieved clinical development [112].

A putative *in vivo* anticoagulant efficacy in mice, with no suggestion of acute side effects, shows the potential of xanthenes **58** and **59** to lead a new class of therapeutic agents in the prevention and treatment of thromboembolic events. These scaffolds with lesser charge density compared to heparins may be expected to cause minimal cross-reactivity with other proteins. Therefore, these compounds are likely to overcome the bleeding complications and hepatic toxicity owing to their minimal charge density. This family of compounds, with a well-defined composition, are also merited with a feasible synthesis protocol [107,113].

A number of viruses use sites on heparan sulfate (HS) as receptors for binding to cells [114]. Mimics of these sequences are likely to interact with the virus in solution, thereby

tying it up and disrupting the viruses interaction with cell surface HS (Figure 14B) [115]. Therefore, the potential of our sulfated small molecules as antivirals was later explored by our group. It was discovery that sulfated xanthenes **58** and **59** were able of decreasing Epstein–Barr virus (EBV) levels in a Burkitt lymphoma (BL) [116]. EBV infects more than 90% of the world population. Following primary infection, EBV persists in an asymptomatic latent state, associated with several diseases, such as BL. To date, there are no available drugs to target latent EBV, and the existing broad-spectrum antiviral drugs are mainly active against lytic viral infection. The fact that compounds **58** and **59** led to a decrease in the EBV DNA present in the Raji cell line (Burkitt lymphoma) was a first indication that these molecules were targeting EBV in its latent state or interfering with episome maintenance. The use of hydroxyurea (an anticancer drug) to reduce EBV DNA load, although having been successful, has the disadvantage of leading to the accumulation of additional mutations in the cellular genome. In this context, the sulfated xanthenes revealed by our group may serve as a starting point for development of alternative molecules to hydroxyurea. In addition, these compounds did not present cytotoxicity at the concentrations tested for their antiviral activity what is relevant for their possible use as antivirals, being potentially specific and not affecting cell viability.

Nature uses sulfation mainly to avoid potential toxicity, so synthesis of non-natural sulfated small molecules could be a way in generating new nontoxic bioactive agents. Zosteric acid, which is a *p*-sulfated cinnamic acid derived from the marine seagrass *Zostera marina*, has received much attention as a potential marine antifoulant product (Figure 14C) [117]. The toxicity studies of zosteric acid showed no measurable LD<sub>50</sub> for larval fish and an acute toxicity profile similar to table sugar. The marine industry is now facing the phase-out of current persistent, bioaccumulative, and toxic biocides that are continuing being released from AF coatings to the environmental, shortening the available alternatives to combat marine biofouling. Developing alternative environmentally friendly and non-toxic AF agents is an urgent demand. The yields of natural compounds from marine organisms are generally poor, hindering their development as AF agents. Moreover, optimizing a microorganism for enhanced production of antifoulant is generally laborious and time consuming. Besides, marine natural products are often structurally too complex to be synthesized on a large scale and are often not compatible with polymer coatings. Synthesis of simple and optimized antifoulants looks like a more sustainable way bringing an opportunity to produce commercial supplies for AF industry without sacrifice natural species. Therefore, in 2017, inspired by the marine zosteric acid molecule, several synthetic sulfated structure-diverse compounds obtained by our group were tested for AF properties [118]. New synthetic AF scaffolds were disclosed in this work, namely xanthone **59**, which exhibited effective anti-settlement response towards the most common biofouling species with worldwide representatives, the *Mytilus galloprovincialis* (EC<sub>50</sub> = 23.19 μM) without causing mortality to this species at any of the tested concentrations (LC<sub>50</sub> > 500 μM), in contrast to the commercial eco-friendly AF agent ECONEA® which showed some toxicity at the higher concentrations tested (LC<sub>50</sub> = 107.78 μM). For the efficacy level of new eco-friendly alternatives, it is highly recommended therapeutic ratios (LC<sub>50</sub>/EC<sub>50</sub>) higher than 15, which is in accordance with the results obtained with this new AF agent. However, while this xanthone **59** was active, other sulfated xanthenes did not show notable activity. These results show that the nature of the scaffold plays a role in placing sulfate groups in favourable position for the activity: while xanthone **59** was highly active, a structure related xanthone in which the *O*-linkage was replaced by a triazole linkage, was not active.

In contrast to the biocide ECONEA, which caused 100% mortality of the marine shrimp *Artemia salina* at 50 μM, compound **59** was not significantly different from filtered seawater, revealing no toxicity even at 250 μM. The nontoxic nature of xanthone **59** was also confirmed by the lack of light radiation inhibition on the *Vibrio fischeri* luminescent assay (LC<sub>50</sub> > 1000 μg/mL). Adding to the low ecotoxicity potential, the bioactive sulfated xanthone is highly water soluble, suggesting also a low bioaccumulation potential, which was proven by in silico calculations of logK<sub>ow</sub> (octanol-water partition

coefficient). In conclusion, the first synthetic xanthone with AF effects was disclosed by our group in 2017 [118], merited with putative eco-friendly label. The viable synthetic process can predict its easy scale-up and future commercialization. This work was the starting point for the development of new optimized and/or diverse xanthenes with AF activity (Sections 2.1 and 2.2) [55].

Natural glycosides of xanthenes demonstrate several biological activities in which the glycosidic moiety showed an important role [18]. In our group, an acetylated xanthone glycoside (**60**, Figure 15) obtained by synthesis was recently shown to have a potent inhibitory effect on glioma cells growth [119]. Acetylated xanthonoside **60** and its parent non-acetylated xanthonoside were first evaluated for their in vitro growth inhibitory effect on A375-C5 (IL-1 insensitive malignant melanoma), MCF-7 (breast adenocarcinoma), and NCI-H460 (non-small-cell lung cancer) cell lines. Acetylated xanthonoside **60** exhibited potent growth inhibitory activity in MCF-7 and NCI-H460 cell lines with GI<sub>50</sub> values of 0.46 and 0.19  $\mu\text{M}$ , respectively, while the non-acetylated xanthonoside was not able to reach 50% of cell growth inhibition. These results put forward the role of the acetyl groups in the potent cell growth inhibitory activity of xanthone **60**. After this promising results, glioblastoma cell lines (U251, U373, and U87MG) growth was also studied in the presence of xanthone **60** and a potent inhibitory activity was found with this xanthone against the referred three lines (GI<sub>50</sub> values between 0.42–0.55  $\mu\text{M}$ ). Association of acetyl groups with inhibition of growth of glioma cell lines had been reported in the natural *O*-acetylated ganglioside GD1b neurostatin, present in the mammalian brain, which showed strong inhibition of astroblast and astrocytoma division and in a previous work of our regarding an acetylated flavonoid glycoside [120]. Acylation is expected to increase the penetration through the cell membrane. However, as acetylated compounds are likely to present poor water solubility and to suffer hydrolysis by esterases, the encapsulation of this acetylated xanthonoside in nanosystems was planned as possible strategy to overcome these limitations. Xanthone **60** was successfully incorporated by us in liposomes while maintaining the inhibitory activity against glioblastoma cell lines [119]. New formulations and/or drug carriers to fight glioma growth with this promising xanthone are being studied by our group.

## 2.6. Chiral Derivatives of Xanthenes


The relationship between chirality and biological activity has been of increasing importance in medicinal chemistry [121], and our group has contributed to this research field with the synthesis of a library of chiral derivatives of xanthenes (CDXs). Our inspiration to follow this way was based on Nature, as an unquestionable successful source of chiral bioactive compounds [122]. Actually, in biological systems, chirality is the rule rather than the exception and the presence of chiral centers in natural products, provides higher affinity and target specificity. Regarding this class of compounds, many naturally occurring xanthenes, isolated from terrestrial and marine sources are chiral, and present a wide range of biological and pharmacological activities [31]. Nevertheless, while biosynthetic pathways frequently give only one enantiomer, the synthetic procedures may allow the preparation of both enantiomers, in addition to the access to structures that otherwise could not be reached [16,123]. Therefore, our main goals were to synthesize bioactive CDXs inspired in natural molecules and/or introduction of chirality in some interesting molecules, as well as obtaining both enantiomers with very high enantiomeric purity to explore enantioselectivity. We consider that it is of crucial importance to study the biological behaviour of each single enantiomer since the physiological properties, such as pharmacodynamics, pharmacokinetics and toxicity, are often different between enantiomers [124]. Moreover, enantioselectivity studies must be performed in the early stage of drug discovery and development. Another reason to work with CDXs was to enlarge chemical and biological spaces. In fact, despite the large structural multiplicity of bioactive xanthenes, only a handful of synthetic chiral derivatives was reported [125,126]. Additionally, the CDXs

were also obtained to achieve other purposes, such as to be used as analytical tools, as it will be covered at the end of this section.

The first CDXs synthesized by our group were inspired in natural molecules, specifically in xanthonolignoids. This natural class of compounds was chosen, as they are interesting bioactive and very promising templates for molecular modifications. They are isolated from plants of the Clusiaceae family (Guttiferae) and comprise a phenylpropane nucleus bounded to a xanthone scaffold by a dioxane moiety, formed by radical oxidative coupling [127]. Our group described, in 1987, the synthesis of *trans*-kielcorin (Figure 3) and its stereoisomer, *cis*-kielcorin, both xanthonolignoids of the kielcorin group [35]. It was the first report of the biomimetic synthesis of these compounds. While the total synthesis of kielcorin derivatives requires severe reaction conditions and many steps, the biomimetic pathway is based on natural building blocks and is achieved by an oxidative coupling of a suitable dihydroxyxanthone with a cinnamyl alcohol derivative, in the presence of an oxidizing agent at room temperature [127]. In 1999, also by a biomimetic approach, the synthesis of *trans*-kielcorin B (Figure 3) and *trans*-isokielcorin B was described by our group [128]. To obtain bioactive analogues with kielcorin scaffold, other constitutional isomers were synthesized by us in 2002, namely *trans*-kielcorin C (61), *trans*-kielcorin D (62), *trans*-isokielcorin D, *cis*-kielcorin C, and *trans*-kielcorin E [59]. Once again, the synthetic approach was performed on a biomimetic way, by oxidative coupling of coniferyl alcohol with an appropriate xanthone. The oxidizing agents Ag<sub>2</sub>O, Ag<sub>2</sub>CO<sub>3</sub>, K<sub>3</sub>[Fe(CN)<sub>6</sub>], among others, were used to investigate the oxidative coupling reactions [129].

Synthetic kielcorins C-E were evaluated for their *in vitro* effect on the growth of three human tumor cell lines, MCF-7 (breast), TK-10 (renal), UACC-62 (melanoma), and on the proliferation of human lymphocytes [62]. The growth inhibitory effect was moderate but in a dose-dependent manner and influenced by the isomerism. The most active compounds were *trans*-kielcorins C (61) and D (62) (Figure 16). The inhibition of human lymphocyte proliferation induced by phytohemagglutinin (PHA) was identified [56]. The high potency and selectivity observed for these compounds suggested that kielcorins might be an important model for developing potent and isoform-selective protein kinase C (PKC) inhibitors. Kielcorins C-E revealed an effect compatible with PKC inhibition similar to that exhibited by chelerythrine, a well-established PKC inhibitor [130]. Previously, synthetic *trans*-kielcorin (Figure 3) and *trans*-isokielcorin B were evaluated and demonstrated protective effect against *tert*-butylhydroperoxide-induced toxicity in freshly isolated rat hepatocytes [50], although in a less extension than their simple oxygenated precursors.

To determine the stereochemistry-activity relationship on the growth inhibitory effects of the kielcorins C-E, chiral liquid chromatography (cLC) methods were developed for their enantioseparation, using polysaccharide-based chiral stationary phases (CSPs) and multimodal elution conditions, in 2004 [131]. Later, the enantiomers of the kielcorins C-E were efficiently separated on a multimilligram scale using an amylose *tris*-3,5-dimethylphenylcarbamate CSP [132]. A solid-phase injection system was developed and combined with a closed loop recycling system to increase the productivity and recovery of the preparative process. The enantiomeric purity was also evaluated being higher than 99%, except for *trans*-kielcorin C (61) [132]. It must be highlighted that the development of methods to obtain and analyse both pure enantiomers has been acquired crucial importance, as are required for biological and pharmacological activity evaluation of both enantiomers [133]. The inhibitory activity of the racemates C-E as well as of the corresponding enantiomers on *in vitro* growth of the human breast adenocarcinoma cell line MCF-7 was evaluated and compared. The most evident enantioselectivity was found between the racemate of *trans*-kielcorin D (62) (inactive) and the active enantiomers (+)-62 and (−)-62 (Figure 16) [68,134–136].




**Figure 16.** Chemical structures of representative bioactive CDXs and examples of enantioselectivity in biological activity.

More recently, in 2012, our group explored another approach to acquire synthetic CDXs in an enantiomerically pure form by binding diverse chiral moieties to an appropriate xanthone scaffold (Figure 16) [137]. Generally, the synthetic strategy used involved the coupling of suitable functionalized xanthenes with both enantiomers of commercially available chiral building blocks, using a coupling reagent in the presence of a catalytic amount of triethylamine (TEA) and tetrahydrofuran as solvent. Through this “chiral pool” strategy, we currently have a large library of CDXs including eighty-six compounds described in literature [135,137].

Considering that carboxyxanthone derivatives are appropriate chemical substrates to perform molecular modifications to obtain diverse derivatives and analogues [138], we selected different compounds, comprising one or more carboxylic groups, to perform the

referred syntheses [68,135–137]. Both enantiomers of a variety of amino alcohols, amines, and amino esters were chosen as chiral building blocks, containing a primary amine as reactive group for amide formation (Figure 17). Until now, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium tetrafluoroborate (TBTU) was demonstrated to be the best coupling reagent to synthesize CDXs. All products have no tendency towards racemization or enantiomeric interconversion. TBTU has been broadly used as an effective reagent for the synthesis of varied classes of compounds [139] however, our group reported for the first time the use of this coupled reagent to synthesize CDXs [137]. All coupling reactions were carried out at room temperature, showing short reactions times (ranging from 20 min to 6 h) and excellent yields (ranging from 92% to 99%) [135–137]. The synthetic methodology proved to be very efficient, with broad-scope applicability, and simple operationally. Moreover, it was found that the synthesis of the CDXs was easily scaled-up to obtain available quantities for biological and pharmacological assays as well as other applications [68,69].



**Figure 17.** General structure of the CDXs with aminoalcohols and amines as CM.

Thirty-one enantiomeric pairs of the synthesized CDXs were evaluated for the *in vitro* growth inhibitory activity in three human tumor cell lines, A375-C5 (melanoma), MCF-7 (breast adenocarcinoma), and NCI-H460 (non-small cell lung cancer) [135,136]. The obtained results allowed to find active chiral compounds for all the tested cells lines, with some showing cell-type selectivity, and to draw SAR considerations. It was found that the nature and position of substituents on the xanthone scaffold and on the aromatic ring of the chiral moiety had a significant influence in determining the growth inhibitory effect. Another feature that has a decisive role on the growth inhibitory effect was the configuration of the stereogenic center(s). The most active CDXs in all human tumor cell lines were (*R,S*)-65 [135] and (*R*)-69 [136] (Figure 16). Both enantiomers of CDX 63 also revealed promising results [136] (Figure 16). The (*S*)-enantiomer of compound 69, showed promising inhibitory activity against A375-C5 and NCI-H460 cell lines; however, it is important to point out the high enantioselectivity observed for MCF-7 tumor cell line with (*S*)-69 showing low inhibitory effect ( $GI_{50} = 112.3 \pm 19.56 \mu\text{M}$ ) and (*R*)-69 presenting a  $GI_{50} = 24.10 \pm 8.49 \mu\text{M}$  [135]. Other interesting examples of enantioselectivity were observed for other enantiomeric pairs of CDXs, such as CDX 64 [135,136]. In addition, *in vitro* DNA crosslinking ability was assessed for the active compounds and the results correlated with *in vitro* cytotoxicity [136]. It was inferred that a possible mechanism of action may involve induction of DNA crosslinking activity. Nevertheless, other mechanisms cannot be excluded and must be explored in further studies.

Other enantioselectivity studies associated with biological activity of CDXs were performed, specifically the *in vitro* and *in silico* inhibition of cyclooxygenases (COX-1 and COX-2) enzymes [140]. All tested CDXs inhibited both enzymes being, in general, the inhibitory effects similar. The only exception was the enantiomeric pair of CDX 70, being the (*R*)-enantiomer more active at inhibiting COX-2 than COX-1 (Figure 16). The inhibitory effects for COX-1 demonstrated to be dependent on the stereochemistry of the compounds. Enantioselectivity was also observed for COX-2 inhibition being the CDXs (*S*)-70 and (*S*)-66 the more active compounds (Figure 16) [140].

Regarding that some CDXs have molecular moieties structurally very similar to some kind of local anaesthetics, the ability to block compound action potentials at the isolated rat sciatic nerve was also investigated [137]. The CDXs (*S*)-70, (*S*)-67 and (*S*)-68 (Figure 16) were chosen for biological evaluation and the results suggested that the nerve

conduction blockade might result predominantly from an action on  $\text{Na}^+$  ionic currents. It was also investigated if the CDXs could prevent hypotonic haemolysis on rat erythrocytes. However, these data suggested that all tested CDXs caused no significant protection against hypotonic when applied in concentrations high enough to block the sciatic nerve conduction in the rat [137].

Additionally, considering that lipophilicity is one of the most important drug-like properties having a great impact in both pharmacokinetics and pharmacodynamics processes, the lipophilicity of a series of CDXs inferred by the partition between octanol and aqueous phase were assessed using four different methods: computational methods, vortex-assisted liquid-liquid microextraction coupled with LC, reversed-phase thin layer chromatography, reversed-phase LC, and biomembranes model by the partition between micelles and aqueous phase [141]. The methodologies and data gathered in this study allowed a better understanding of lipophilicity of this important class of compounds, which highlights the need to have different lipophilicity measurements to take conscious decisions in the hit to drug optimization process.

Different types of CSPs, namely Pirkle type, macrocyclic antibiotic and polysaccharide-based, were considered for quantification of the enantiomeric ratio, to explore the structure-enantioresolution relationship (SER) as well to investigate the chiral recognition mechanisms of the synthesized libraries of CDXs. All explored CSPs were suitable for quantification of the enantiomeric ratio of the majority of CDXs of all synthesized libraries. The resolution of seven enantiomeric pairs of CDXs on (*S,S*)-Whelk-O1 and L-phenylglycine CSPs was systematically investigated using multimodal elution conditions (normal, polar-organic, and reversed-phase) [142]. The (*S,S*)-Whelk-O1 CSP, under polar-organic conditions, demonstrated a high power of resolution for the CDXs possessing an aromatic moiety linked to the stereogenic center, the enantioselectivity ( $\alpha$ ) and resolution ( $R_s$ ) ranged from 1.91 to 7.55 and from 6.71 to 24.16, respectively. The chiral recognition mechanisms were investigated for (*S,S*)-Whelk-O1 CSP by molecular docking and were in accordance with the experimental chromatographic parameters. The simultaneous  $\pi$ - $\pi$  interactions that may be established by the phenyl group at the stereogenic center as well as the xanthone scaffold with the selector demonstrated to be essential for enantioselective recognition [142]. Lately, 32 new CDXs were investigated on (*S,S*)-Whelk-O1 CSP only in polar organic mode with acetonitrile/methanol (50:50 *v/v*) as mobile phase. The values of  $\alpha$  and  $R_s$  ranged from 1.41 to 6.25 and from 1.29 to 17.20, respectively. Generally, the (*R*)-enantiomer was the first to elute. All the enantiomeric pairs were enantioseparated, even those without an aromatic moiety linked to the stereogenic center. The chiral recognition mechanisms by molecular docking were consistent with the chromatographic parameters and elution orders. Several structural requirements were revealed as being important for enantioselectivity: the xanthone tricyclic ring aligned with phenanthryl moiety of the (*S,S*)-Whelk-O1 selector in order to maximize  $\pi$ - $\pi$  stacking interactions; the aromatic ring of the chiral moiety of xanthone derivatives established  $\pi$ - $\pi$  stacking interactions with the 3,5-dinitrophenyl group of the selector and H-bonding interactions between the xanthone carbonyl and the NH amide of the selector [143].

In a study considering macrocyclic antibiotic CSPs for determination of the enantiomeric ratio, to explore the SER and the chiral recognition mechanisms by molecular docking, fourteen new CDXs were evaluated in Chirobiotic T, Chirobiotic TAG, Chirobiotic V and Chirobiotic R under multimodal elution conditions. The best  $\alpha$  and  $R_s$  were achieved on Chirobiotic R and Chirobiotic T CSPs, under normal elution conditions, with  $R_s$  ranging from 1.25 to 2.50 and from 0.78 to 2.06, respectively. The chiral recognition mechanisms by molecular docking were able to estimate the resolution for CDXs with a success rate of 92%. The calculations also showed that each macrocyclic antibiotic CSP exhibits rather different binding patterns. The shape and the surface of the chirobiotic CSP, the general chemical structure and not only the position of the stereogenic centers of the CDXs played an important role in the overall retention of the enantiomers by the CSPs [144]. Recently, the same four macrocyclic antibiotic CSPs were used for a systematic

study of enantioseparation of thirty-one new CDXs, confirming the applicability of these CSPs for the enantioseparation of this class of compounds [145]. It was found that their applicability increased considering the complementary profile in enantioselectivity of the different macrocyclic antibiotic CSPs. Higher resolutions were obtained for the CDXs evaluated compared to our previous work [143], and additional information about chiral recognition mechanisms was provided [145].


Regarding polysaccharide-based CSPs, the SER of twelve enantiomeric pairs of CDXs were investigated on *tris*-3,5-dimethylphenylcarbamates of cellulose and amylose and *tris*-3,5-dimethoxyphenylcarbamate of amylose under multimodal elution conditions. All the enantiomeric mixtures of CDXs were enantioseparated with very high values of  $\alpha$  and  $R_s$ , ranging from 1.43 to 12.41 and from 1.48 to 10.29, respectively. Amylose *tris*-3,5-dimethylphenylcarbamate CSP under polar organic elution conditions presented the best results. The influence of the mobile phases and structural features of the CSPs and CDXs on chiral discrimination were also discussed. Considering the overall results, the chiral recognition of CDXs on polysaccharide-based CSPs depends not only on the nature of the CSPs but also on the mobile phase composition. The chemical bridges of the CDXs, the substitution of the xanthone scaffold, as well as the position of the stereogenic center had great influence on the enantioselectivity [143].

Recently, the SER, the chiral recognition mechanisms, and binding of CDXs on human serum albumin (HSA) CSP were also investigated (values of  $\alpha$  and  $R_s$  ranged from 1.40 to 9.16 and 1.51 to 4.97, respectively). Percentages of binding ranged from 79.02 to 99.99%. The highest affinity values were achieved for the CDXs bearing bulky alkyl or aryl groups in the chiral side chain, suggesting that the hydrophobicity of the CDXs was important for HSA binding process. A good agreement (71%) between docking studies and experimental results was achieved, indicating that CDXs fit within the hydrophobic pocket of subdomain IIIA [146].

In fact, the excellent results of SER of CDXs with a diversity of CSPs justify the investigation of CDXs as selectors for cLC. Thus, in addition to the interesting biological activities, CDXs have also been explored as selectors for CSPs [68,69,147]. CDXs possess all the necessary attributes to constitute good selectors for cLC due to the 3D quasi-planar structure and peculiar electronic properties of the xanthone scaffold and the diverse association with a variety of functional groups and chiral moieties, what results in structural characteristics that afford the establishment of different types of interactions as well as the three-dimensionality, factors that influence the enantioselectivity, similarly with the basic scaffold of Pirkle-type CSPs (Figure 18) [148]. Accordingly, six CDXs in enantiomerically pure form were covalently linked to silica gel through a spacer yielding the corresponding CSPs. The synthetic methodology involved only a few steps and the reactions provided good yields. These new CSPs are based on a completely different scaffold of small molecules of Pirkle's CSPs [148]. The resolution capability of these CSPs was evaluated using different chemical classes of chiral compounds under multimodal elution conditions. A library of CDXs was also evaluated in order to explore the principle of reciprocity as well as the chiral self-recognition phenomenon. In general, the CSPs provided high specificity for the enantiomeric mixtures of CDXs evaluated, mainly under normal elution mode [69,147].

Recently, from the development of new CSPs for cLC based on the most promising CDXs as chiral selectors, twelve new CSPs were successfully prepared starting from suitable functionalized small molecules including xanthone and benzophenone derivatives. The chiral selectors comprise one, two, three, or four chiral moieties. The evaluation of the new CSPs was done with different classes of chiral compounds, including a library of CDXs. Specificity for enantioseparation of some CDXs was observed. Besides, assessment of chiral recognition mechanisms was performed by molecular docking approach, which were in accordance with the chromatographic parameters. X-Ray analysis was also used to establish the structure of a chiral selector 3D. Excellent values of  $\alpha$  (5.08) and  $R_s$  (3.13) were obtained for 4-methoxy- $\alpha$ -methylbenzylamine, in reversed-phase mode, using CH<sub>3</sub>CN/H<sub>2</sub>O/TEA: 80/20/0.01 as mobile phase. Moreover, enantioselectivity was also obtained for other

analytes, including the commercial amines *N*-benzyl-1-(1-naphthyl)ethylamine and alanine-2-naphthylamide, although with low resolution [68].




**Figure 18.** Schematic comparison of the general structure of a Pirkle's CSP with a general xanthone small molecule as a selector.

Our group provided a significant contribution synthesizing a bioinspired library of CDXs, through a very convenient synthetic strategy, and exploring the enantioselectivity in biological activities for this class of compounds. Some CDXs proved to act as blockers of sciatic nerve transmission, as inhibitors of growth of human tumor cell lines and cyclooxygenase enzymes; in some cases, being the activity dependent on the stereochemistry. Additionally, enantioseparation studies and enantiomeric purity evaluation of the CDXs have been conducted using different types of CSPs, namely Pirkle-type, macrocyclic glycopeptide-based, polysaccharide-based, and HSA CSPs. Besides the potential as new drugs, CDXs present structural features with interest as chiral selectors for CSPs in LC. Analytical application for these small molecules as chiral selectors for LC was discovered by your group for the first time.

## 2.7. Thioxanthenes

Thioxanthenes are isosters of xanthenes. Structurally, they are *S*-heterocycles with a dibenzo- $\gamma$ -thiopyrone scaffold, being described as an important class of molecules for their diverse biological properties, particularly their antitumor activity [126,149,150]. Their tricyclic scaffolds and the biological activities profile have led to the definition of thioxanthenes as privileged structures, similarly to what happens with xanthenes [98]. The first thioxanthenes described as potential antitumor agents were hycanthone [151] and lucanthone [152], used as antischistosomal drugs (Figure 19). They were also described as antitumor agents with several mechanisms of action: DNA intercalation, inhibition of nucleic acid biosyntheses, inhibition of topoisomerases and apurinic endonuclease 1 [153]. Nonetheless, they were promptly withdrawn due to mutagenicity [154] caused by the methylene linked to C-4 [155]. Thereafter, other thioxanthenes such as SR233377 [150,156,157] and SSR271425 [157,158] were tested in clinical trials as antitumor agents but were found to be cardiotoxic [159] (Figure 19). Despite that, the photoinitiator 1-chloro-4-propoxy-9*H*-thioxanthen-9-one was described as being safe and not genotoxic (Figure 19), according to GHS and to Directive 67/548/EEC. Consequently, our group considered that the design of thioxanthenes without a methyl group or a methylene bridge at C-4 (lucanthone, hycanthone, SR233377, and SR271425), but with a propoxyl group at C-4, such as 1-chloro-4-propoxy-9*H*-thioxanthen-9-one, would be a suitable starting point for the discovery of new potential anticancer drugs.



**Figure 19.** Structures of historically relevant thioxanthenes.

However, we were aware that anticancer drugs often have low efficiency in the treatment and cure of cancer due to the acquired or intrinsic resistance of tumor cells to these agents [160]. Indeed, resistance to one drug often implies resistance to a series of different drugs, which are structural and functionally very distinct, the designated multiple drugs resistance (MDR) [160]. The MDR is heterogeneous, involving a combination of mechanisms, such as alteration of membrane transports [160]. P-glycoprotein (P-gp) or ABCB1 is the best characterized efflux pump implicated in MDR [161].

P-gp is an apical membrane transporter whose aim is to protect cells against xenobiotics and cellular toxicants. The overexpression of P-gp confers significant resistance to a wide variety of neutral and cationic hydrophobic chemotherapeutic substrates [162]. P-gp inhibitors generally have a logP of 2.92 or higher, a long chain to strengthen the link to P-gp; and at least one protonable nitrogen that can establish ionic and ion-dipole bonds [163–165]. Tariquidar and zosuquidar, belonging to the 3rd generation P-gp inhibitors, are examples of compounds that respect those characteristics [166]. Therefore, we concluded that antitumor agents that are P-gp inhibitors by themselves could represent a good first step toward the development of multi-functional drugs called dual-activity agents. Simultaneous modulation of multiple biological targets can be beneficial for the treatment of diseases with complex etiologies such as cancer. Recently, there has been a paradigm shift in drug design towards the development of multifunctional drugs, which means that a compound can reach multiple targets [167,168].

Thus, our aim was to design new dual ligands that would have anticancer activity and simultaneously avoid MDR through P-gp inhibition, by hybridizing a thioxanthone scaffold (antitumor activity) and an amine (group present in P-gp inhibitors). In fact, next generation of drugs will focus on more than one target, because this will really accelerate progress against complex diseases [169]. A docking study was performed using a dataset of approximately 1000 virtual C1 aminated thioxanthenes and two human P-gp models. Lipinski rule of five and other features described as important for P-gp inhibition, such as logP value of at least 2.92 or higher [164,165] were applied as queries to the initial library of aminated thioxanthenes. The molecules that passed through these filters were docked into the transmembrane domains (TMD) and nucleotide binding domains (NBD) of P-gp. Twenty-seven thioxanthenes with the highest affinity towards P-gp were then synthesized by C(1)-N Ullmann cross coupling using conventional heating at 100 °C for 48h or MW-promoted heating at 205 °C for 50 min, in presence of  $K_2CO_3$  base. Dealkylation was performed using boron bromide,  $BBr_3$  [170]. Secondary thioxanthonic products of the performed reactions without an amine at C-1 were also included in the

in vitro studies. After purification and structural elucidation, a rhodamine-123 (P-gp substrate) accumulation assay [171] was performed in order to detect which thioxanthenes were modulating P-gp activity. In this assay, two chronic myeloid leukemia cell lines were used, a sensitive cell line (K562) and a resistant cell line that overexpresses P-gp (K562Dox). The most potent P-gp inhibitors were **71**, **72**, and **73**, which increased the accumulation of Rh123 similarly to the known P-gp inhibitor quinidine (Figure 20). In order to determine how those compounds were interacting with P-gp, the measurement of their effect on the rate of P-gp ATP hydrolysis was performed to differentiate between thioxanthenes that were increasing the P-gp-mediated ATP hydrolysis (competitive inhibitors or substrates) and thioxanthenes that were diminishing P-gp-mediated ATP hydrolysis (non-competitive inhibitors) [170,172,173]. From the compounds that had caused accumulation of rh123 in the cells, 25% were acting as competitive and 75% as non-competitive inhibitors of P-gp (some examples are represented on Figure 20A). Thioxanthenes **72**, **73**, and **76** were the best non-competitive inhibitors of P-gp, blocking the ATPase activity, whereas **77** and **78** were the best competitive inhibitors of P-gp, stimulating the ATP hydrolysis and being themselves transported by the pump [170] (Figure 20). The results obtained for thioxanthonic derivatives [170] and several commercially available drugs [171,174] in the in vitro ATPase assay led to the establishment of a pharmacophore for competitive and non-competitive P-gp inhibitory activity. In order to access the antitumor activity against tumor cell lines, a cell growth inhibitory effect (sulphorodamine-B assay) of 27 thioxanthenes was performed on K562 (chronic myeloid leukemia cell line) [170], MCF-7 (breast cancer cell line), NCI-H460 (non-small cell lung cancer, NSCLC), and A375-C5 (melanoma cell line) [175]. Concerning the K562 cell line, six compounds presented GI<sub>50</sub> inferior to 10 µM (**74**, **75**, **76**, **78**, **79**, and **80**) (Figure 20); and eight presented GI<sub>50</sub> between 10 and 20 µM, with no significant decrease in cellular viability of MRC-5 (non-tumor cell line). The most potent cell growth inhibitor thioxanthone was 1-[[2-(diethylamino)ethyl]amino]-4-propoxy-9H-thioxanthen-9-one (**80**), with a GI<sub>50</sub> of 1.9 µM. This compound has a 2-(diethylamino)ethylamine side chain at position 1, equally to lucanthenone (Figure 19), the first thioxanthone described as a potential antitumor agent which reached phase II clinical trials for glioblastoma multiforme [153,176]. Concerning the solid tumor cell lines, two compounds, **80** and the thioxanthone C4 acetyl derivative **82** (Figure 20B) were found to be the most potent on the studied cell lines, presenting GI<sub>50</sub> concentration lower than 10 µM [175].

As the most potent compound on the four tested tumor cell lines was **80**, this compound, along with its hydrochloride salt, **80**·HCl, were further investigated to discover its cellular mechanism of action. An MTT assay using MCF-7 cells showed that 6 h treatment with **80**·HCl was sufficient to interfere with the cellular metabolic activity, cell survival and proliferation; and for longer periods no recovery was observed, suggesting that the effect is irreversible. Besides, **80**·HCl was acting preferably as a cytotoxic rather than as a cytostatic compound. At 10 µM and higher **80**·HCl concentrations there were alteration in cellular morphology which were suggestive of apoptosis.

A TUNEL assay and a flow cytometry analysis following Annexin V-FITC and propidium iodide (PI) showed that treatment with 10 µM **80**·HCl induced apoptosis in approximately 50% of the cells analysed [175]. Besides, **80** decreases the viability of melanoma cells by modulation of autophagy, causing accumulation of autophagosomes and the formation of autophagolysosomes at the GI<sub>50</sub> concentration. An increase in LC3-II levels was also observed, which was reverted by 3-methyladenine (3-MA) (an early stage autophagy-inhibitor) but further increased by E-64d/pepstatin (late-stage autophagy inhibitors). Lastly, 3-MA also reverted the effect of **80** in cellular viability; and may, therefore, serve as a lead compound for the development of autophagy modulators with antitumor activity [177].





Figure 20. Cont.



**Figure 20.** Thioxanthenes and their biological activities: (A) Competitive and noncompetitive P-gp inhibitors. (B) P-gp activators/inducers.

As **80** was considered a hit compound, with *in vitro* antitumor potential by modulating autophagy and apoptosis in human tumor cell lines, the mechanism of action of **80.HCl** was further investigated using *in vitro* and mouse xenograft tumor models of non-small-cell lung carcinoma (NSCLC). It was discovered that **80.HCl** caused abnormal cellular cholesterol localization and reduced the growth of human NSCLC cells *in vitro* and of NSCLC xenografts in mice, without presenting toxicity to the animals [178]. As perturbations in cholesterol localization or trafficking have been shown to affect cellular viability, this results provide new insights into a promising new mechanism of action of **80**, which may be relevant for the development of anticancer therapeutic strategies which target cholesterol transport [178].

Being the antitumor and P-gp inhibitory mechanisms of action already explored individually, the most promising thioxanthenes were further investigated on K562Dox cell line (derived from K562 by doxorubicin stimulated overexpression of P-gp) with the purpose of analysing if thioxanthenes were effectively capable of reducing cell growth of a resistant cell line. Six of the compounds had a  $GI_{50}$  value inferior to  $20 \mu\text{M}$  on K562Dox cell line, suggesting a potential dual mechanism of action: P-gp and cell growth inhibitory activity. Notably, **80** was 9-fold more potent than doxorubicin in this cell line. Furthermore, six compounds significantly decreased the doxorubicin  $GI_{50}$  value on K562Dox cell line. At  $1 \mu\text{M}$ , **71** and **73** caused a high decrease in doxorubicin  $GI_{50}$  on K562Dox cell line but almost did not affect doxorubicin  $GI_{50}$  on K562 sensitive cell line (the effect is mainly due to P-gp inhibitory activity), whereas **80** caused a high decrease in doxorubicin  $GI_{50}$  on both cell lines (the effect is also due to **80** own cytotoxic activity) [170] (Figure 20).

As a large number of studies indicated that other ABC transporters besides P-gp are involved in the efflux of endogenous molecules and xenobiotics out of the cell, our group decided to investigate the interaction of thioxanthenes with other transporters, such as the multidrug-resistance associated transporter 1 (MRP1 or ABCC1), MRP2 (or ABCC2, cMOAT), MRP3 (or ABCC3) and the breast cancer associated protein (BCRP or ABCG2, MXR) [179]. Undoubtedly, a characteristic of all generations of P-gp inhibitors is that they are frequently multi-target inhibitors of other ABC transporters, as described for tariquidar [180], as these pumps share structural and functional similarities. A colorimetric-based ATPase assay using membrane vesicles from mammalian cells overexpressing a selected human ABC transporter protein (P-gp, MRP1, MRP2, MRP3, or BCRP) was

performed by our group. Thioxanthone **78** was able to inhibit all the tested pumps, and **71** was able to inhibit all the pumps except MRP2 [179].

One of the problems regarding P-gp inhibitors is the pharmacokinetic interactions due to the fact that they can also be substrates or inhibitors of cytochrome p450, that will require the use of a higher dose of the cytotoxic compound to achieve therapeutic success [179]. As CYP3A4 has wide range of substrates and it is the subfamily of CYP responsible for the phase I metabolism of 50% of drugs administered to humans, a CYP3A4 luciferin-based luminescence assay was performed. The tested thioxanthenes interfered with CYP3A4 activity in vitro (inhibitors or substrates), which was in accordance with the in silico prediction. It was found that **71** and **78** presented IC<sub>50</sub> values for CYP3A4 inhibition of approximately 1–2 µM, but the inhibition was almost total for concentrations close to 100 µM [179].

More recently, new chiral thioxanthenes with aminated substituents at C-1 (2-amino-1-propanol, 1-amine-2-propanol, leucinol, and valinol) were synthesized in enantiomerically pure form in order to analyse the effect of the stereochemistry in P-gp modulation (Figure 21). All chiral thioxanthenes at 20 µM significantly decreased the intracellular accumulation of a P-gp fluorescent substrate Rh123, suggesting an increment in the activity of the efflux pump. Therefore, these thioxanthenes were shown to behave as P-gp activators, increasing the efflux of substrates without interfering with P-gp levels of expression. Moreover, (*R*)-1-((1-hydroxypropan-2-yl)amino)-4-propoxy-9*H*-thioxanthen-9-one (**89**), after 24 h of incubation, was also able to significantly increased P-gp expression (P-gp inducer) [181]. Concerning thioxanthenes induction mechanism, one of the possibilities is the transcriptional activation of the MDR1 gene expression that involves the activation of the pregnane X receptor (PXR) [182,183]. Furthermore, no significant differences were detected in the activity of the enantiomeric pairs towards P-gp [181]. Still concerning P-gp induction in other organisms, using high throughput RNA sequencing, the transcriptional response of the filamentous fungus *Neurospora crassa* to thioxanthone derivatives with antitumor activity (**75**, **81**, and **86**) revealed that there is an induction of ABC transporters in that fungus, particularly *atrB* and *cdr4*, which is a common consequence of the treatment with (thio)xanthenes [94]. Moreover, a group of genes were downregulated by the tested thioxanthenes during oxidative stress [94]. While screening for potential P-gp inhibitors that increased the accumulation of known P-gp substrate Rh123, some of the tested thioxanthenes caused the opposite effect, decreasing the Rh123 accumulation ratio. This effect is compatible with a possible P-gp activation, and such compounds are potential protectors against toxic effects induced by P-gp substrates [170]. Indeed, P-gp, besides being responsible for multidrug resistance of neoplastic cells to cancer therapy, is also constitutively expressed in many excretory and barrier tissues and, due to its wide substrate specificity, can play a crucial role in limiting the absorption and increasing the efflux of harmful xenobiotics. This defence mechanism can be very important at the intestinal barrier, as it can decrease the intestinal absorption of toxic xenobiotics [184].

Some thioxanthonic derivatives were tested for P-gp activation and/or induction, and its ability to protect Caco-2 cells from the herbicide paraquat induced toxicity was assessed. All tested thioxanthenes (**83–87**) at 20 µM caused a significant increase in both P-gp expression (inducer) and activity (activator) as evaluated by flow cytometry using the UIC2 antibody and rhodamine 123, respectively (Figure 20). They also increased P-gp ATPase activity in MDR1-Sf9 membrane vesicles, indicating that all compounds were P-gp substrates. Paraquat cytotoxicity was significantly reduced in the presence of four thioxanthone derivatives (**83–86**), and this protective effect was reversed upon incubation with a specific P-gp inhibitor. In silico studies suggested a potential co-transport mechanism of thioxanthenes and paraquat [184]. The most potent P-gp inducer and activator, **85**, can be considered a new and promising antidotal model against P-gp substrates cytotoxicity (Figure 20) [184]. Therefore, it was important to find a simple, rapid and economical method for the analysis and quantification of this thioxanthone. A reverse-phase high-performance liquid chromatography (HPLC) using a C18 column and a mobile phase

composed of methanol-water (90/10, *v/v*) with 1% (*v/v*) TEA, at a flow rate of 1 mL/min, was used for chromatographic separation. The method was validated according to ICH and it was selective, as there were no interferences of endogenous compounds with the same retention time. Also, the developed method was linear for **85** concentrations between 0.5 and 150  $\mu\text{M}$ . Therefore, this HPLC method could be used to detect trace amounts of these thioxanthone in biological samples [185].




Figure 21. Chiral thioxanthones.

Besides antitumor and ABC transporters inhibition, thioxanthones represent a class of compounds with many other potential and diverse biological activities. As several of these compounds were described as antimicrobial agents, our group decided to also study the potential of some of our in-house thioxanthones to fight biofouling. In this study, significant anti-settlement responses were identified in the presence of thioxanthone **75** ( $\text{EC}_{50} = 3.53 \mu\text{M}$ ) and **86** ( $\text{EC}_{50} = 28.60 \mu\text{M}$ ), concomitantly with low toxicity to mussel larvae ( $\text{LC}_{50} > 500 \mu\text{M}$ ). Thus, adding to their already known pharmacological actions, these thioxanthones also revealed AF activity. Exposure of plantigrade larvae to compound **75** altered the abundance of proteins involved in major cellular metabolic processes as glycolysis/gluconeogenesis, lysosomal protein degradation, or proteins that are constituents of the cytoskeleton. With some of these constitutive proteins having an important role in metabolism and cellular functions, it is possible that **75** affects the metabolism of a broad number of organisms. However, in contrast to AF xanthones described in previous section (2.1, 2.2, and 2.5), thioxanthones **75** and **86** were found to be toxic (100% and 50% mortality at 50  $\mu\text{M}$ , respectively) to *Artemia salina*. A QSAR model was constructed that will orient the design of future novel active compounds [55].


Thioxanthones have aroused enormous interest in the preceding decades because of their multidimensional health effects, as anticancer agents and MDR-reverter agents. Moreover, they are privileged structures and promising biomolecules due to their potential role as protective agents against toxic xenobiotics or due to its ability to inhibit settlement and growth of fouling organisms. These aspects and their impact on drug bioavailability have recently been reviewed in [186]. However, much more is still to be explored in the future concerning their applications in health and industry.

### 3. Conclusions

This review aims to give a perspective of the approaches and strategies used in our group to discover bioactive xanthone derivatives, and/or pharmacological probes, from natural and synthetic sources. Given the objective of this review, most of the references indicated throughout the text correspond mainly to the contribution of our group in this area. The hit compounds discovered for several targets and with diverse biological activities were highlighted and could be useful models to develop a vast number of heterocyclic privileged scaffolds. Not only is important to reach high-affinity hits but a strong investment should follow on safety, PK, process chemistry and comprehensive SAR understanding. Being focusing in the (thio)xanthonic scaffold is considered one of the strengths of our research group. However, we also aim for diversity and innovation by researching less explored areas (such as marine natural products), and most importantly by following a multi- and interdisciplinary approach, engaging chemistry of natural products, organic and medicinal chemistry, structure determination and purification, green chemistry, physicochemical properties and ADMET, validated in silico and HTS screenings, intellectual protection, drug delivery systems, etc. In summary, taking into account the chemical “family tree” based on xanthone (Figure 22), our group has:

- (1) isolated new compounds from terrestrial and marine sources and/or analyzed species not yet studied with regard to their secondary metabolites;
- (2) used Nature-based strategies to guide the synthetic ways whenever possible;
- (3) synthesized these compounds for structure elucidation purposes to obtain them through “greener” methods and in quantities suitable for biological/pharmacological assays, as well as to obtain nature-based analogues with improved druglike properties;
- (4) contributed with new data in the area of NMR and X-ray crystallography;
- (5) evaluated several biological activities for different chemical families of xanthone derivatives; the main focus was in the area of antitumor and antimicrobial agents, especially taking into account MDR, which we believe should be pursuit in Academia; other areas of intervention include cardiovascular, antimalarial, anti-inflammatory, anti-obesity, hepatoprotection, etc. More recently, the area related to the discovery of environmental-benign AF agents was also explored;
- (6) explored the mechanisms of action, SAR and structure-activity-properties-relationship (SAPR);
- (7) formulated some compounds in nanoparticles, liposomes and proliposomes (drug delivery systems), especially with xanthenes with potential antitumor activity;
- (8) determined the drug-likeness of some hit compounds (ADMET assays), as this should be carried out as soon as possible in the pipeline of drug discovery and development;
- (9) obtained several chiral derivatives of xanthenes and studied enantioseparation and enantioselectivity with regard to various biological activities, as well as analytical applications as chiral selectors for liquid chromatography.

Finally, some of our hit xanthone derivatives may be emphasized as follows. As antitumor agents, the selective and poor water-soluble 1-carbaldehyde-3,4-dimethoxy-xanthone (**7**) and the drug-like P-gp dual inhibitor 1-[[2-(diethylamino)ethyl]amino]-4-propoxy-9*H*-thioxanthen-9-one (**80**) stand out; both proved their activity in patient derived-cells and in in vivo models, respectively. The first one still needs to be optimized due to unfavourable PK profile and the hit-to-lead optimization stage is ongoing based on the investigation of bioisosters of the aldehyde including ketones, ketoesters and boronic acids/esters. Since we have recently disclosed that the molecular mechanism of antitumor action of the dual inhibitor is related to the cholesterol transport, a balanced activity for both P-gp/antitumor activity can be tuned by structure-based design.



**Figure 22.** Our chemical “family tree” based on xanthone.

Concerning antimicrobial agents, marine-derived halogenated xanthenes **28–31** were the most promising and efforts must be directed to improve solubility and to integrate chemical features that would overcome MDR such as the ones performed for other chemotherapies. This approach already allowed us to obtain chlorinated/aminated xanthone derivatives with broad activity spectrum also against parasitic protozoa. There are many examples of effective anti-infective drugs, which also do not obey the usual drug-likeness rules; therefore, considering the urgent need for new antimicrobial agents we can hope that marine-derived xanthenes will be very useful models in this area of research. Sulfated groups have proven to be an important molecular feature for the recognition of several targets both in human (coagulation cascade) and in virus as well as to render mimetic derivatives of marine secondary metabolites with antifouling activity. Although the proof-of-concept for this class of xanthenes is more advanced concerning safety, PK, and bioaccumulation profile, the chemical process to scale-up for kg applications is still a difficulty to surpass. Considering the analytical applications as chiral selectors for LC, the best enantioselectivity results were achieved for xanthone-phenylglycinol-derived CSPs. The next strategy to improve the design and obtain more efficient CSPs possessing wider applicability will be the preparation of selectors based on CDXs comprising one or more bulky aromatic moieties and polar groups to maximize  $\pi$ - $\pi$  stacking and H-bonding, essential interactions for enantiorecognition.

**Author Contributions:** M.M.M.P. conceived, wrote and revised the manuscript, while all authors gave significant contributions in writing: simple oxygenated xanthenes (E.S.), prenylated xanthenes (H.C., S.C.), halogenated, aminated, and carboxyxanthenes (D.I.S.P.R.), sulfated and/or glycosylated xanthenes (M.C.-d.-S.), chiral derivatives of xanthenes (C.F. and M.E.T.), thioxanthenes (A.P.). E.S.

and D.I.S.P.R. gave additional support in the discussion and final revision. All authors agreed to the final version of the manuscript.

**Funding:** This research was supported by national funds through FCT (Foundation for Science and Technology) within the scope of UIDB/04423/2020, UIDP/04423/2020, and under the project PTDC/SAU-PUB/28736/2017 (reference POCI-01-0145-FEDER-028736), co-financed by COMPETE 2020, Portugal 2020 and the European Union through the ERDF and by FCT through national funds, as well as structured program of R&D&I ATLANTIDA—Platform for the monitoring of the North Atlantic Ocean and tools for the sustainable exploitation of the marine resources (reference NORTE-01-0145-FEDER-000040), supported by the North Portugal Regional Operational Programme(NORTE2020), through the European Regional Development Fund (ERDF), and CHIRALBIO ACTIVE-PI-3RL-IINFACTS-2019.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Biswas, S.C.; Sen, R.K. X-ray crystallographic studies of xanthenes. *Indian J. Pure Appl. Phys.* **1982**, *20*, 414.
2. Onuma, S.; Iijima, K.; Oonishi, I. Structure of xanthone. *Acta Crystallogr. Sect. C* **1990**, *46*, 1725–1727. [[CrossRef](#)]
3. Gales, L.; Damas, A.M. Xanthenes-A Structural Perspective. *Curr. Med. Chem.* **2005**, *12*, 2499–2515. [[CrossRef](#)] [[PubMed](#)]
4. Hepworth, H. *Chemical Synthesis: Studies in the Investigation of Natural Organic Products*; Blackie and Son: London, UK, 1924; Volume 44, pp. 120–121.
5. Henry, L.; Cavenfou, J.-B. *J. Pharm. Chim.* **1821**, *7*, 178.
6. Kamal, A.; Husain, S.A.; Noorani, R.; Murtaza, N.; Qureshi, I.H.; Qureshi, A.A. Studies in the biochemistry of microorganisms. XI. Isolation of tajixanthone, shamixanthone, ajamxanthone, shahenxanthone, najamxanthone, radixanthone and mannitol from mycelium of *Aspergillus stellatus*, Curzi. *Pak. J. Sci. Indus. Res.* **1970**, 251–255, in press.
7. Michael, A. On the action of aromatic oxy-acids on phenols. *Am. Chem. J.* **1883**, *5*, 81–97.
8. Kostanecki, S.V. Über das Gentsin. *Mon. Chem. Verwandte Teile And. Wiss.* **1891**, *12*, 205–210. [[CrossRef](#)]
9. Organic Syntheses. Available online: <http://online.fliphtml5.com/jocd/yqzh/#p=1> (accessed on 2 December 2020).
10. Goldberg, I. Ueber phenylirungen bei gegenwart von kupfer als katalysator. *Ber. Dtsch. Chem. Ges.* **1906**, *39*, 1691–1692. [[CrossRef](#)]
11. Schmid, W. Ueber das Mangostin. *Justus Liebigs Ann. Chem.* **1855**, *93*, 83–88. [[CrossRef](#)]
12. Rai, M.; Chikindas, M.L. *Natural Antimicrobials in Food Safety and Quality*; CAB International: Wallingford, UK, 2011.
13. Negi, J.S.; Bisht, V.K.; Singh, P.; Rawat, M.S.M.; Joshi, G.P. Naturally Occurring Xanthenes: Chemistry and Biology. *J. Appl. Chem.* **2013**, *2013*, 621459. [[CrossRef](#)]
14. Madalena, M.M.P. Editorial [Hot Topic: Xanthone (Dibenzo- $\gamma$ -Pyrone): An Interesting Framework In Medicinal Chemistry (Guest Editor: Madalena M.M. Pinto)]. *Curr. Med. Chem.* **2005**, *12*, 2411. [[CrossRef](#)]
15. Vieira, L.M.M.; Kijjoa, A. Naturally-Occurring Xanthenes: Recent Developments. *Curr. Med. Chem.* **2005**, *12*, 2413–2446. [[CrossRef](#)] [[PubMed](#)]
16. Sousa, M.E.; Pinto, M.M.M. Synthesis of Xanthenes: An Overview. *Curr. Med. Chem.* **2005**, *12*, 2447–2479. [[CrossRef](#)] [[PubMed](#)]
17. Silva, A.M.S.; Pinto, D.C.G.A. Structure Elucidation of Xanthone Derivatives: Studies of Nuclear Magnetic Resonance Spectroscopy. *Curr. Med. Chem.* **2005**, *12*, 2481–2497. [[CrossRef](#)] [[PubMed](#)]
18. Pinto, M.M.M.; Sousa, M.E.; Nascimento, M.S.J. Xanthone Derivatives: New Insights in Biological Activities. *Curr. Med. Chem.* **2005**, *12*, 2517–2538. [[CrossRef](#)] [[PubMed](#)]
19. Riscoe, M.; Kelly, J.X.; Winter, R. Xanthenes as Antimalarial Agents: Discovery, Mode of Action, and Optimization. *Curr. Med. Chem.* **2005**, *12*, 2539–2549. [[CrossRef](#)] [[PubMed](#)]
20. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; et al. Methods for drug discovery: Development of potent, selective, orally effective cholecystokinin antagonists. *J. Med. Chem.* **1988**, *31*, 2235–2246. [[CrossRef](#)]
21. Nguyen, H.T.; Lallemand, M.-C.; Boutefnouchet, S.; Michel, S.; Tillequin, F. Antitumor Psoropermum Xanthenes and Sarcomelicope Acridones: Privileged Structures Implied in DNA Alkylation. *J. Nat. Prod.* **2009**, *72*, 527–539. [[CrossRef](#)]
22. Lesch, B.; Bräse, S. A Short, Atom-Economical Entry to Tetrahydroxanthenones. *Angew. Chem. Int. Ed.* **2004**, *43*, 115–118. [[CrossRef](#)]
23. Hesham, R.E.-S.; Dina, M.H.E.-G.; Mai, A.E.-B.; Mervat, F.Z.; Ulf, G.; Sonny, L.; Rob, V. Naturally Occurring Xanthenes; Latest Investigations: Isolation, Structure Elucidation and Chemosystematic Significance. *Curr. Med. Chem.* **2009**, *16*, 2581–2626. [[CrossRef](#)]

24. Demirkiran, O. Xanthonones in Hypericum: Synthesis and Biological Activities. In *Bioactive Heterocycles III*; Khan, M.T.H., Ed.; Springer: Berlin/Heidelberg, Germany, 2007; pp. 139–178. [[CrossRef](#)]
25. Wezeman, T.; Masters, K.-S. Chapter 12 Xanthonones are Privileged Scaffolds in Medicinal Chemistry—But are they Over-privileged? In *Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation*; The Royal Society of Chemistry: London, UK, 2016; pp. 312–347. [[CrossRef](#)]
26. Peres, V.; Nagem, T.J.; De Oliveira, F.F. Tetraoxygenated naturally occurring xanthonones. *Phytochemistry* **2000**, *55*, 683–710. [[CrossRef](#)]
27. Loureiro, D.R.P.; Soares, J.X.; Costa, J.C.; Magalhães, Á.F.; Azevedo, C.M.G.; Pinto, M.M.M.; Afonso, C.M.M. Structures, activities and drug-likeness of anti-infective xanthone derivatives isolated from the marine environment: A review. *Molecules* **2019**, *24*, 243. [[CrossRef](#)] [[PubMed](#)]
28. Kumla, D.; Dethoup, T.; Gales, L.; Pereira, J.A.; Freitas-Silva, J.; Costa, P.M.; Silva, A.M.S.; Pinto, M.M.M.; Kijjoa, A. Erubescensoic Acid, a new polyketide and a xanthonopyrone SPF-3059-26 From the culture of the marine sponge-associated fungus *penicillium erubescens* KUFA 0220 and Antibacterial activity evaluation of some of its constituents. *Molecules* **2019**, *24*, 208. [[CrossRef](#)] [[PubMed](#)]
29. Resende, D.; Pereira-Terra, P.; Inácio, Â.; Costa, P.; Pinto, E.; Sousa, E.; Pinto, M. Lichen Xanthonones as Models for New Antifungal Agents. *Molecules* **2018**, *23*, 2617. [[CrossRef](#)] [[PubMed](#)]
30. Pinto, M.M.M.; Castanheiro, R.A.P.; Kijjoa, A. Xanthonones from Marine-Derived Microorganisms: Isolation, Structure Elucidation and Biological Activities. In *Encyclopedia of Analytical Chemistry*; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2006. [[CrossRef](#)]
31. Masters, K.-S.; Bräse, S. Xanthonones from Fungi, Lichens, and Bacteria: The Natural Products and Their Synthesis. *Chem. Rev.* **2012**, *112*, 3717–3776. [[CrossRef](#)] [[PubMed](#)]
32. Bugni, T.S.; Ireland, C.M. Marine-derived fungi: A chemically and biologically diverse group of microorganisms. *Nat. Prod. Rep.* **2004**, *21*, 143–163. [[CrossRef](#)]
33. Roberts, J.C. Naturally Occurring Xanthonones. *Chem. Rev.* **1961**, *61*, 591–605. [[CrossRef](#)]
34. Narosa, G.B. (Ed.) Natural Prenylated xanthonones: Chemistry and biological activities. In *Natural Products: Chemistry, Biochemistry and Pharmacology*; Publishing House PVT: New Dehli, India, 2009.
35. Mesquita, A.A.L.; Gottlieb, O.R.; Madalena, M.D.M. Xanthonolignoids from *Kielmeyera coriacea*. *Phytochemistry* **1987**, *26*, 2045–2048. [[CrossRef](#)]
36. Pinto, M.; Nascimento, M.S.J.; Gonzalez, M.J.; Mondranondra, I.-O. Anticomplementary activity and constituents of *Cratoxylum maingayi* DYER. *Pharm. Pharmacol. Lett.* **1997**, *7*, 128–130.
37. Kijjoa, A.; José, M.; Gonzalez, T.G.; Pinto, M.M.M.; Damas, A.M.; Mondranondra, I.O.; Silva, A.M.S.; Herz, W. Xanthonones from *Cratoxylum maingayi*. *Phytochemistry* **1998**, *49*, 2159–2162. [[CrossRef](#)]
38. Gonzalez, M.J.; Nascimento, M.S.J.; Cidade, H.M.; Pinto, M.M.M.; Kijjoa, A.; Anantachoke, C.; Silva, A.M.S.; Herz, W. Immunomodulatory activity of xanthonones from *Calophyllum teysmannii* var. *inophylloide*. *Planta Med.* **1999**, *65*, 368–371. [[CrossRef](#)] [[PubMed](#)]
39. Kijjoa, A.; Gonzalez, M.J.; Pinto, M.M.M.; Silva, A.M.S.; Anantachoke, C.; Herz, W. Xanthonones from *Calophyllum teysmannii* var. *inophylloide*. *Phytochemistry* **2000**, *55*, 833–836. [[CrossRef](#)] [[PubMed](#)]
40. Kijjoa, A.; Gonzalez, M.J.; Pinto, M.M.M.; Nascimento, M.S.J.; Campos, N.; Mondranondra, I.O.; Silva, A.M.S.; Eaton, G.; Herz, W. Cytotoxicity of prenylated xanthonones and other constituents from the wood of *Garcinia merguensis*. *Planta Med.* **2008**, *74*, 864–866. [[CrossRef](#)] [[PubMed](#)]
41. Freitas, V.L.S.; Ribeiro da Silva, M.D.M.C. Influence of Hydroxyl Functional Group on the Structure and Stability of Xanthone: A Computational Approach. *Molecules* **2018**, *23*, 2962. [[CrossRef](#)] [[PubMed](#)]
42. Pinto, M.; Nascimento, M.S.J. Anticomplementary activity of hydroxy- and methoxyxanthonones. *Pharm. Pharmacol. Lett.* **1997**, *7*, 125–127.
43. Fernandes, E.G.R.; Silva, A.M.S.; Cavaleiro, J.A.S.; Silva, F.M.; Fernanda, M.; Borges, M.; Pinto, M.M.M. <sup>1</sup>H and <sup>13</sup>C NMR Spectroscopy of mono-, di-, tri- and tetrasubstituted xanthonones. *Magn. Reson. Chem.* **1998**, *36*, 305–309. [[CrossRef](#)]
44. Gales, L.; De Sousa, M.E.; Pinto, M.M.M.; Kijjoa, A.; Damas, A.M. Naturally occurring 1,2,8-trimethoxy-xanthone and biphenyl ether intermediates leading to 1,2-dimethoxy-xanthone. *Acta Crystallogr. Sect. C Cryst. Struct. Commun.* **2001**, *57*, 1319–1323. [[CrossRef](#)]
45. Gales, L.; Sousa, M.E.; Pinto, M.M.M.; Damas, A.M. 3,4-Dihydroxy-9H-xanthen-9-one trihydrate. *Acta Crystallogr. Sect. E Struct. Rep. Online* **2005**, *61*, o2213–o2215. [[CrossRef](#)]
46. Resende, D.I.S.P.; Durães, F.; Maia, M.; Sousa, E.; Pinto, M.M.M. Recent advances in the synthesis of xanthonones and azaxanthonones. *Org. Chem. Front.* **2020**. [[CrossRef](#)]
47. Teixeira, M.; Afonso, C.M.; Pinto, M.M.; Barbosa, C.M. A validated HPLC method for the assay of xanthone and 3-methoxyxanthone in PLGA nanocapsules. *J. Chromatogr. Sci.* **2003**, *41*, 371–376. [[CrossRef](#)]
48. Pedro, M.; Cerqueira, F.; Sousa, M.E.I.; Nascimento, M.S.J.; Pinto, M. Xanthonones as inhibitors of growth of human cancer cell lines and Their effects on the proliferation of human lymphocytes In Vitro. *Bioorg. Med. Chem.* **2002**, *10*, 3725–3730. [[CrossRef](#)]
49. Cidade, H.; Rocha, V.; Palmeira, A.; Marques, C.; Tiritan, M.E.; Ferreira, H.; Lobo, J.S.; Almeida, I.F.; Sousa, M.E.; Pinto, M. In silico and in vitro antioxidant and cytotoxicity evaluation of oxygenated xanthone derivatives. *Arab. J. Chem.* **2017**. [[CrossRef](#)]

50. Fernandes, E.R.; Carvalho, F.D.; Remião, F.G.; Bastos, M.L.; Pinto, M.M.; Gottlieb, O.R. Hepatoprotective Activity of Xanthenes and Xanthonolignoids Against tert-Butylhydroperoxide-Induced Toxicity in Isolated Rat Hepatocytes—Comparison with Silybin. *Pharm. Res. Off. J. Am. Assoc. Pharm. Sci.* **1995**, *12*, 1756–1760. [[CrossRef](#)]
51. Pinto, E.; Afonso, C.; Duarte, S.; Vale-Silva, L.; Costa, E.; Sousa, E.; Pinto, M. Antifungal Activity of Xanthenes: Evaluation of their Effect on Ergosterol Biosynthesis by High-performance Liquid Chromatography. *Chem. Biol. Drug Des.* **2011**, *77*, 212–222. [[CrossRef](#)] [[PubMed](#)]
52. Bessa, L.J.; Palmeira, A.; Gomes, A.S.; Vasconcelos, V.; Sousa, E.; Pinto, M.; Da Costa, P.M. Synergistic effects between thioxanthenes and oxacillin against methicillin-resistant staphylococcus aureus. *Microb. Drug Resist.* **2015**, *21*, 404–415. [[CrossRef](#)] [[PubMed](#)]
53. Resende, D.I.S.P.; Pereira-Terra, P.; Moreira, J.; Freitas-Silva, J.; Lemos, A.; Gales, L.; Pinto, E.; De Sousa, M.E.; Da Costa, P.M.; Pinto, M.M.M. Synthesis of a Small Library of Nature-Inspired Xanthenes and Study of Their Antimicrobial Activity. *Molecules* **2020**, *25*, 2405. [[CrossRef](#)]
54. Urbatzka, R.; Freitas, S.; Palmeira, A.; Almeida, T.; Moreira, J.; Azevedo, C.; Afonso, C.; Correia-da-Silva, M.; Sousa, E.; Pinto, M.; et al. Lipid reducing activity and toxicity profiles of a library of polyphenol derivatives. *Eur. J. Med. Chem.* **2018**, *151*, 272–284. [[CrossRef](#)]
55. Almeida, J.R.; Palmeira, A.; Campos, A.; Cunha, I.; Freitas, M.; Felpeto, A.B.; Turkina, M.V.; Vasconcelos, V.; Pinto, M.; Correia-Da-silva, M.; et al. Structure-antifouling activity relationship and molecular targets of bio-inspired(Thio)xanthenes. *Biomolecules* **2020**, *10*, 1126. [[CrossRef](#)]
56. Gnerre, C.; Thull, U.; Gaillard, P.; Carrupt, P.-A.; Testa, B.; Fernandes, E.; Silva, F.; Pinto, M.; Pinto, M.M.M.; Wolfender, J.-L.; et al. Natural and Synthetic Xanthenes as Monoamine Oxidase Inhibitors: Biological Assay and 3D-QSAR. *Helv. Chim. Acta* **2001**, *84*, 552–570. [[CrossRef](#)]
57. Silva, R.; Sousa, E.; Carmo, H.; Palmeira, A.; Barbosa, D.J.; Gameiro, M.; Pinto, M.; De Lourdes Bastos, M.; Remião, F. Induction and activation of P-glycoprotein by dihydroxylated xanthenes protect against the cytotoxicity of the P-glycoprotein substrate paraquat. *Arch. Toxicol.* **2014**, *88*, 937–951. [[CrossRef](#)]
58. Martins, E.; Silva, V.; Lemos, A.; Palmeira, A.; Puthongking, P.; Sousa, E.; Rocha-Pereira, C.; Ghanem, C.I.; Carmo, H.; Remião, F.; et al. Newly Synthesized Oxygenated Xanthenes as Potential P-Glycoprotein Activators: In Vitro, Ex Vivo, and In Silico Studies. *Molecules* **2019**, *24*, 707. [[CrossRef](#)] [[PubMed](#)]
59. Saraiva, L.; Fresco, P.; Pinto, E.; Sousa, E.; Pinto, M.; Gonçalves, J. Synthesis and in vivo modulatory activity of protein kinase C of xanthone derivatives. *Bioorg. Med. Chem.* **2002**, *10*, 3219–3227. [[CrossRef](#)]
60. Saraiva, L.; Fresco, P.; Pinto, E.; Sousa, E.; Pinto, M.; Gonçalves, J. Inhibition of protein kinase C by synthetic xanthone derivatives. *Bioorg. Med. Chem.* **2003**, *11*, 1215–1225. [[CrossRef](#)]
61. Rosa, G.P.; Palmeira, A.; Resende, D.I.S.P.; Almeida, I.F.; Kane-Pagès, A.; Barreto, M.C.; Sousa, E.; Pinto, M.M.M. Xanthenes for melanogenesis inhibition: Molecular docking and QSAR studies to understand their anti-tyrosinase activity. *Bioorg. Med. Chem.* **2021**, *29*, 115873. [[CrossRef](#)] [[PubMed](#)]
62. Sousa, E.P.; Silva, A.M.S.; Pinto, M.M.M.; Pedro, M.M.; Cerqueira, F.A.M.; Nascimento, M.S.J. Isomeric Kielcorins and Dihydroxyxanthenes: Synthesis, Structure Elucidation, and Inhibitory Activities of Growth of Human Cancer Cell Lines and on the Proliferation of Human Lymphocytes In Vitro. *Helv. Chim. Acta* **2002**, *85*, 2862–2876. [[CrossRef](#)]
63. Gomes, S.; Raimundo, L.; Soares, J.; Loureiro, J.B.; Leão, M.; Ramos, H.; Monteiro, M.N.; Lemos, A.; Moreira, J.; Pinto, M.; et al. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. *Cancer Lett.* **2019**, *446*, 90–102. [[CrossRef](#)] [[PubMed](#)]
64. Silva, V.; Cerqueira, F.; Nazareth, N.; Medeiros, R.; Sarmiento, A.; Sousa, E.; Pinto, M. 1,2-Dihydroxyxanthone: Effect on A375-C5 Melanoma Cell Growth Associated with Interference with THP-1 Human Macrophage Activity. *Pharmaceuticals* **2019**, *12*, 85. [[CrossRef](#)]
65. Gomes, A.S.; Brandão, P.; Fernandes, C.S.G.; Da Silva, M.; De Sousa, M.; Pinto, M.M.M. Drug-like Properties and ADME of Xanthone Derivatives: The Antechamber of Clinical Trials. *Curr. Med. Chem.* **2016**, *23*, 3654–3686. [[CrossRef](#)]
66. Sousa, E.; Palmeira, A.; Cordeiro, A.S.; Sarmiento, B.; Ferreira, D.; Lima, R.T.; Helena Vasconcelos, M.; Pinto, M. Bioactive xanthenes with effect on P-glycoprotein and prediction of intestinal absorption. *Med. Chem. Res.* **2013**, *22*, 2115–2123. [[CrossRef](#)]
67. Resende, D.I.S.P.; Almeida, M.C.; Maciel, B.; Carmo, H.; Sousa Lobo, J.; Dal Pozzo, C.; Cravo, S.M.; Rosa, G.P.; Kane-Pagès, A.; Do Carmo Barreto, M.; et al. Efficacy, Stability, and Safety Evaluation of New Polyphenolic Xanthenes Towards Identification of Bioactive Compounds to Fight Skin Photoaging. *Molecules* **2020**, *25*, 2782. [[CrossRef](#)]
68. Phyo, Y.Z.; Teixeira, J.; Tiritan, M.E.; Cravo, S.; Palmeira, A.; Gales, L.; Silva, A.M.S.; Pinto, M.M.M.; Kijjoo, A.; Fernandes, C. New chiral stationary phases for liquid chromatography based on small molecules: Development, enantioresolution evaluation and chiral recognition mechanisms. *Chirality* **2020**, *32*, 81–97. [[CrossRef](#)] [[PubMed](#)]
69. Fernandes, C.; Tiritan, M.E.; Cravo, S.; Phyo, Y.Z.; Kijjoo, A.; Silva, A.M.S.; Cass, Q.B.; Pinto, M.M.M. New chiral stationary phases based on xanthone derivatives for liquid chromatography. *Chirality* **2017**, *29*, 430–442. [[CrossRef](#)] [[PubMed](#)]
70. Teixeira, M.; Pedro, M.; Nascimento, M.S.J.; Pinto, M.M.M.; Barbosa, C.M. Development and characterization of PLGA nanoparticles containing 1,3-dihydroxy-2-methylxanthone with improved antitumor activity on a human breast cancer cell line. *Pharm. Dev. Technol.* **2019**, *24*, 1104–1114. [[CrossRef](#)] [[PubMed](#)]

71. Teixeira, M.; Alonso, M.J.; Pinto, M.M.M.; Barbosa, C.M. Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone. *Eur. J. Pharm. Biopharm.* **2005**, *59*, 491–500. [[CrossRef](#)] [[PubMed](#)]
72. Malta, R.; Loureiro, J.B.; Costa, P.; Sousa, E.; Pinto, M.; Saraiva, L.; Amaral, M.H. Development of lipid nanoparticles containing the xanthone LEM2 for topical treatment of melanoma. *J. Drug Deliv. Sci. Technol.* **2020**. [[CrossRef](#)]
73. Loureiro, D.R.P.; Magalhães, Á.F.; Soares, J.X.; Pinto, J.; Azevedo, C.M.G.; Vieira, S.; Henriques, A.; Ferreira, H.; Neves, N.; Bousbaa, H.; et al. Yicathins B and C and Analogues: Total Synthesis, Lipophilicity and Biological Activities. *ChemMedChem* **2020**, *15*, 749–755. [[CrossRef](#)]
74. Silva, V.; Gil-Martins, E.; Rocha-Pereira, C.; Lemos, A.; Palmeira, A.; Puthongking, P.; Sousa, E.; De Lourdes Bastos, M.; Remião, F.; Silva, R. Oxygenated xanthenes as P-glycoprotein modulators at the intestinal barrier: In vitro and docking studies. *Med. Chem. Res.* **2020**, *29*, 1041–1057. [[CrossRef](#)]
75. Baell, J.; Walters, M.A. Chemistry: Chemical con artists foil drug discovery. *Nature* **2014**, *513*, 481–483. [[CrossRef](#)]
76. Baell, J.B.; Nissink, J.W.M. Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations. *ACS Chem. Biol.* **2018**, *13*, 36–44. [[CrossRef](#)]
77. Pinto, M.M.M.; Castanheiro, R.A.P. Synthesis of prenylated xanthenes: An overview. *Curr. Org. Chem.* **2009**, *13*, 1215–1240. [[CrossRef](#)]
78. Azevedo, C.M.G.; Afonso, C.M.M.; Soares, J.X.; Reis, S.; Sousa, D.; Lima, R.T.; Vasconcelos, M.H.; Pedro, M.; Barbosa, J.; Gales, L.; et al. Pyranoxanthenes: Synthesis, growth inhibitory activity on human tumor cell lines and determination of their lipophilicity in two membrane models. *Eur. J. Med. Chem.* **2013**, *69*, 798–816. [[CrossRef](#)] [[PubMed](#)]
79. Castanheiro, R.A.P.; Pinto, M.M.M.; Cravo, S.M.M.; Pinto, D.C.G.A.; Silva, A.M.S.; Kijjoo, A. Improved methodologies for synthesis of prenylated xanthenes by microwave irradiation and combination of heterogeneous catalysis (K10 clay) with microwave irradiation. *Tetrahedron* **2009**, *65*, 3848–3857. [[CrossRef](#)]
80. Azevedo, C.M.G.; Afonso, C.M.M.; Sousa, D.; Lima, R.T.; Helena Vasconcelos, M.; Pedro, M.; Barbosa, J.; Corrêa, A.G.; Reis, S.; Pinto, M.M.M. Multidimensional optimization of promising antitumor xanthone derivatives. *Bioorg. Med. Chem.* **2013**, *21*, 2941–2959. [[CrossRef](#)] [[PubMed](#)]
81. França, F.; Silva, P.M.A.; Soares, J.X.; Henriques, A.C.; Loureiro, D.R.P.; Azevedo, C.M.G.; Afonso, C.M.M.; Bousbaa, H. A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel. *Molecules* **2020**, *25*, 5845. [[CrossRef](#)] [[PubMed](#)]
82. Epifano, F.; Genovese, S.; Menghini, L.; Curini, M. Chemistry and pharmacology of oxyprenylated secondary plant metabolites. *Phytochemistry* **2007**, *68*, 939–953. [[CrossRef](#)]
83. Nakatani, K.; Nakahata, N.; Arakawa, T.; Yasuda, H.; Ohizumi, Y. Inhibition of cyclooxygenase and prostaglandin E2 synthesis by  $\gamma$ -mangostin, a xanthone derivative in mangosteen, in C6 rat glioma cells. Abbreviations: AA, arachidonic acid; BSA, bovine serum albumin; COX, cyclooxygenase; COX-1, constitutive COX; COX-2, inducible COX; cPLA2, cytosolic PLA2; EMEM, Eagle's minimum essential medium; ERK, extracellular signal regulated kinase; HEPES, 2-[4-(2-Hydroxyethyl)-1-piperazinyl]ethanesulfonic acid; MAPK, mitogen-activated protein kinase; PGE2, prostaglandin E2; sPLA2, secretory phospholipase A2; TBST, Tris-buffered saline containing 0.05% Tween 20. *Biochem. Pharmacol.* **2002**, *63*, 73–79. [[CrossRef](#)]
84. Castanheiro, R.A.P.; Pinto, M.M.M.; Silva, A.M.S.; Cravo, S.M.M.; Gales, L.; Damas, A.M.; Nazareth, N.; Nascimento, M.S.J.; Eaton, G. Dihydroxyxanthenes prenylated derivatives: Synthesis, structure elucidation, and growth inhibitory activity on human tumor cell lines with improvement of selectivity for MCF-7. *Bioorg. Med. Chem.* **2007**, *15*, 6080–6088. [[CrossRef](#)]
85. Castanheiro, R.A.P.; Silva, A.M.S.; Campos, N.A.N.; Nascimento, M.S.J.; Pinto, M.M.M. Antitumor activity of some prenylated xanthenes. *Pharmaceuticals* **2009**, *2*, 33–43. [[CrossRef](#)]
86. Palmeira, A.; Paiva, A.; Sousa, E.; Seca, H.; Almeida, G.M.; Lima, R.T.; Fernandes, M.X.; Pinto, M.; Vasconcelos, M.H. Insights into the in vitro antitumor mechanism of action of a new pyranoxanthone. *Chem. Biol. Drug Des.* **2010**, *76*, 43–58. [[CrossRef](#)]
87. Paiva, A.M.; Sousa, M.E.; Camões, A.; Nascimento, M.S.J.; Pinto, M.M.M. Prenylated xanthenes: Antiproliferative effects and enhancement of the growth inhibitory action of 4-hydroxytamoxifen in estrogen receptor-positive breast cancer cell line. *Med. Chem. Res.* **2012**, *21*, 552–558. [[CrossRef](#)]
88. Leão, M.; Gomes, S.; Pedraza-Chaverri, J.; Machado, N.; Sousa, E.; Pinto, M.; Inga, A.; Pereira, C.; Saraiva, L.  $\alpha$ -Mangostin and Gambogic Acid as Potential Inhibitors of the p53–MDM2 Interaction Revealed by a Yeast Approach. *J. Nat. Prod.* **2013**, *76*, 774–778. [[CrossRef](#)] [[PubMed](#)]
89. Lemos, A.; Leão, M.; Soares, J.; Palmeira, A.; Pinto, M.; Saraiva, L.; Sousa, M.E. Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction. *Med. Chem. Res.* **2016**, *36*, 789–844. [[CrossRef](#)] [[PubMed](#)]
90. Inga, A.; Pinto, M.M.d.M.; Saraiva, L.H.A.; Sousa, M.E.d.S.P.d.; Pereira, C.I.F.; Paiva, A.M.G.; Leão, M.V.C.F. Inhibitors of p53-mdm2 Interaction. WO/2013/105037, 7 February 2013.
91. Liu, J.; Zhou, F.; Zhang, L.; Wang, H.; Zhang, J.; Zhang, C.; Jiang, Z.; Li, Y.; Liu, Z.; Chen, H. DMXAA-pyranoxanthone hybrids enhance inhibition activities against human cancer cells with multi-target functions. *Eur. J. Med. Chem.* **2018**, *143*, 1768–1778. [[CrossRef](#)] [[PubMed](#)]
92. Paiva, A.M.; Pinto, R.A.; Teixeira, M.; Barbosa, C.M.; Lima, R.T.; Vasconcelos, M.H.; Sousa, E.; Pinto, M. Development of noncytotoxic PLGA nanoparticles to improve the effect of a new inhibitor of p53-MDM2 interaction. *Int. J. Pharm.* **2013**, *454*, 394–402. [[CrossRef](#)]

93. Paiva, A.M.; Teixeira, M.; Pereira, R.; Barbosa, C.M.; Sousa, E.; Pinto, M.M.M. Development and validation of an HPLC method for the quantification of a cytotoxic dihydropyranoxanthone in biodegradable nanoparticles. *Int. J. Drug Deliv.* **2013**, *5*, 224–232.
94. Pedro Gonçalves, A.; Silva, N.; Oliveira, C.; Kowbel, D.J.; Glass, N.L.; Kijjoo, A.; Palmeira, A.; Sousa, E.; Pinto, M.; Videira, A. Transcription profiling of the *Neurospora crassa* response to a group of synthetic (thio)xanthenes and a natural acetophenone. *Genom. Data* **2015**, *4*, 26–32. [[CrossRef](#)] [[PubMed](#)]
95. Le Pogam, P.; Boustie, J. Xanthenes of Lichen Source: A 2016 Update. *Molecules* **2016**, *21*, 294. [[CrossRef](#)] [[PubMed](#)]
96. Dayan, F.E.; Romagni, J.G. Lichens as a potential source of pesticides. *Pestic. Outlook* **2001**, *12*, 229–232. [[CrossRef](#)]
97. Sousa, E.; Paiva, A.; Nazareth, N.; Gales, L.; Damas, A.M.; Nascimento, M.S.J.; Pinto, M. Bromoalkoxyxanthenes as promising antitumor agents: Synthesis, crystal structure and effect on human tumor cell lines. *Eur. J. Med. Chem.* **2009**, *44*, 3830–3835. [[CrossRef](#)]
98. Sun, R.-R.; Miao, F.-P.; Zhang, J.; Wang, G.; Yin, X.-L.; Ji, N.-Y. Three new xanthone derivatives from an algal isolate of *Aspergillus wentii*. *Magn. Reson. Chem.* **2013**, *51*, 65–68. [[CrossRef](#)]
99. Cruz, M.I.; Cidade, H.; Pinto, M. Dual/multitargeted xanthone derivatives for Alzheimer’s disease: Where do we stand? *Future Med. Chem.* **2017**, *9*, 1611–1630. [[CrossRef](#)] [[PubMed](#)]
100. Cruz, I.; Puthongking, P.; Cravo, S.; Palmeira, A.; Cidade, H.; Pinto, M.; Sousa, E. Xanthone and Flavone Derivatives as Dual Agents with Acetylcholinesterase Inhibition and Antioxidant Activity as Potential Anti-Alzheimer Agents. *J. Chem.* **2017**, *2017*, 16. [[CrossRef](#)]
101. Lemos, A.; Gomes, A.S.; Loureiro, J.B.; Brandão, P.; Palmeira, A.; Pinto, M.M.M.; Saraiva, L.; Sousa, M.E. Synthesis, Biological Evaluation, and In Silico Studies of Novel Aminated Xanthenes as Potential p53-Activating Agents. *Molecules* **2019**, *24*, 1975. [[CrossRef](#)] [[PubMed](#)]
102. Portela, C.; Afonso, C.M.M.; Pinto, M.M.M.; João Ramos, M. Definition of an electronic profile of compounds with inhibitory activity against hematin aggregation in malaria parasite. *Bioorg. Med. Chem.* **2004**, *12*, 3313–3321. [[CrossRef](#)] [[PubMed](#)]
103. Portela, C.; Afonso, C.M.M.; Pinto, M.M.M.; Ramos, M.J. Receptor–drug association studies in the inhibition of the hematin aggregation process of malaria. *FEBS Lett.* **2003**, *547*, 217–222. [[CrossRef](#)]
104. Portela, C.; Afonso, C.M.M.; Pinto, M.M.M.; João Ramos, M. Computational studies of new potential antimalarial compounds—Stereo-electronic complementarity with the receptor. *J. Comput.-Aided Mol. Des.* **2003**, *17*, 583–595. [[CrossRef](#)] [[PubMed](#)]
105. Portela, C.; Afonso, C.M.M.; Pinto, M.M.M.; Lopes, D.; Nogueira, F.; Do Rosário, V. Synthesis and Antimalarial Properties of New Chloro-9H-xanthenes with an Aminoalkyl Side Chain. *Chem. Biodivers.* **2007**, *4*, 1508–1519. [[CrossRef](#)]
106. Neves, A.R.; Correia-da-Silva, M.; Sousa, E.; Pinto, M. Strategies to overcome heparins’ low oral bioavailability. *Pharmaceuticals* **2016**, *9*, 37. [[CrossRef](#)]
107. Desai, U.R. The promise of sulfated synthetic small molecules as modulators of glycosaminoglycan function. *Future Med. Chem.* **2013**, *5*, 1363–1366. [[CrossRef](#)]
108. Correia-da-Silva, M.; Sousa, E.; Duarte, B.; Marques, F.; Carvalho, F.; Cunha-Ribeiro, L.M.; Pinto, M.M.M. Polysulfated Xanthenes: Multipathway Development of a New Generation of Dual Anticoagulant/Antiplatelet Agents. *J. Med. Chem.* **2011**, *54*, 5373–5384. [[CrossRef](#)]
109. Imran, M.; Arshad, M.S.; Butt, M.S.; Kwon, J.-H.; Arshad, M.U.; Sultan, M.T. Mangiferin: A natural miracle bioactive compound against lifestyle related disorders. *Lipids Health Dis.* **2017**, *16*, 84. [[CrossRef](#)] [[PubMed](#)]
110. Rashid, Q.; Abid, M.; Jairajpuri, M. Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition. *J. Nat. Sci. Biol. Med.* **2014**, *5*, 36–42. [[CrossRef](#)] [[PubMed](#)]
111. Pinto, M.; Sousa, M.E.; Da Silva, M.C.; Marques, F.; Carvalho, F. Patente Portuguesa N° 104739: Xantonas Sulfatadas e Análogos Xantônicos Glicosilados Sulfatados com Actividade Anticoagulante e Processos Para a Sua Preparação. Portuguese Patent n° 104739, Boletim da Propriedade Industrial n° 47/2011, 9 March 2011.
112. Neves, A.R.; Correia-da-Silva, M.; Sousa, E.; Pinto, M. Structure-activity relationship studies for multitarget antithrombotic drugs. *Future Med. Chem.* **2016**, *8*, 2305–2355. [[CrossRef](#)] [[PubMed](#)]
113. Rashid, Q.; Singh, P.; Abid, M.; Jairajpuri, M.A. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin. *J. Thromb. Thrombolysis* **2012**, *34*, 251–259. [[CrossRef](#)]
114. Kaltenebach, D.D.; Jaishankar, D.; Hao, M.; Beer, J.C.; Volin, M.V.; Desai, U.R.; Tiwari, V. Sulfotransferase and Heparanase: Remodeling Engines in Promoting Virus Infection and Disease Development. *Front. Pharmacol.* **2018**, *9*. [[CrossRef](#)]
115. Daniel, K.A.; Rami, A.A.-H. Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies. *Curr. Med. Chem.* **2020**, *27*, 3412–3447. [[CrossRef](#)]
116. Lima, R.T.; Seca, H.; Palmeira, A.; Fernandes, M.X.; Castro, F.; Correia-da-Silva, M.; Nascimento, M.S.J.; Sousa, E.; Pinto, M.; Vasconcelos, M.H. Sulfated small molecules targeting EBV in Burkitt lymphoma: From in silico screening to the evidence of in vitro effect on viral episomal DNA. *Chem. Biol. Drug Des.* **2013**, *81*, 631–644. [[CrossRef](#)]
117. Vilas-Boas, C.; Sousa, E.; Pinto, M.; Correia-da-Silva, M. An antifouling model from the sea: A review of 25 years of zosteric acid studies. *Biofouling* **2017**, *33*, 927–942. [[CrossRef](#)]
118. Almeida, J.R.; Correia-Da-Silva, M.; Sousa, E.; Antunes, J.; Pinto, M.; Vasconcelos, V.; Cunha, I. Antifouling potential of Nature-inspired sulfated compounds. *Sci. Rep.* **2017**, *7*. [[CrossRef](#)]

119. Alves, A.; Correia-da-Silva, M.; Nunes, C.; Campos, J.; Sousa, E.; Silva, P.M.A.; Bousbaa, H.; Rodrigues, F.; Ferreira, D.; Costa, P.C.; et al. Discovery of a new xanthone against glioma: Synthesis and Development of (Pro)liposome Formulations. *Molecules* **2019**, *24*, 409. [[CrossRef](#)]
120. Neves, A.R.; Correia-da-Silva, M.; Silva, P.M.A.; Ribeiro, D.; Sousa, E.; Bousbaa, H.; Pinto, M. Synthesis of new glycosylated flavonoids with inhibitory activity on cell growth. *Molecules* **2018**, *23*, 1093. [[CrossRef](#)] [[PubMed](#)]
121. Tiritan, M.E.; Ribeiro, A.R.; Fernandes, C.; Pinto, M.M.M. Chiral pharmaceuticals. In *Encyclopedia of Chemical Technology*; Kirk-Othmer, M., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2016.
122. Lanzotti, V. Drugs based on natural compounds: Recent achievements and future perspectives. *Phytochem. Rev.* **2014**, *13*, 725–726. [[CrossRef](#)]
123. Carlos Miguel Goncalves, A.; Carlos Manuel Magalhaes, A.; Madalena Maria Magalhaes, P. Routes to Xanthenes: An Update on the Synthetic Approaches. *Curr. Org. Chem.* **2012**, *16*, 2818–2867. [[CrossRef](#)]
124. Blaser, H.-U. Chirality and its implications for the pharmaceutical industry. *Rend. Lincei* **2013**, *24*, 213–216. [[CrossRef](#)]
125. Fernandes, C.; Carraro, M.L.; Ribeiro, J.; Araujo, J.; Tiritan, M.E.; Pinto, M.M.M. Synthetic chiral derivatives of xanthenes: Biological activities and enantioselectivity studies. *Molecules* **2019**, *24*, 791. [[CrossRef](#)] [[PubMed](#)]
126. Araújo, J.; Fernandes, C.; Pinto, M.; Elizabeth Tiritan, M. Chiral derivatives of xanthenes with antimicrobial activity. *Molecules* **2019**, *24*, 314. [[CrossRef](#)]
127. Pinto, M.M.M.; Sousa, E.P. Natural and synthetic xanthonolignoids: Chemistry and biological activities. *Curr. Med. Chem.* **2003**, *10*, 1–12. [[CrossRef](#)]
128. Fernandes, E.G.R.; Pinto, M.M.M.; Silva, A.M.S.; Cavaleiro, J.A.S.; Gottlieb, O.R. Synthesis and structural elucidation of xanthonolignoids: Trans-(±)-kielcorin B and trans-(±)-isokielcorin B. *Heterocycles* **1999**, *51*, 821–828. [[CrossRef](#)]
129. Emília Sousa, M.; Afonso, C.M.M.; Pinto, M.M.M. Quantitative Analysis of Kielcorins in Biomimetic Synthesis by Liquid Chromatography/UV Detection. *J. Liq. Chromatogr. Relat. Technol.* **2003**, *26*, 29–41. [[CrossRef](#)]
130. Saraiva, L.; Fresco, P.; Pinto, E.; Sousa, E.; Pinto, M.; Gonçalves, J. Inhibition of  $\alpha$ ,  $\beta$ I,  $\delta$ ,  $\eta$  and  $\zeta$  protein kinase C isoforms by xanthonolignoids. *J. Enzym. Inhib. Med. Chem.* **2003**, *18*, 357–370. [[CrossRef](#)]
131. Sousa, E.P.; Tiritan, M.E.; Oliveira, R.V.; Afonso, C.M.M.; Cass, Q.B.; Pinto, M.M.M. Enantiomeric resolution of kielcorin derivatives by HPLC on polysaccharide stationary phases using multimodal elution. *Chirality* **2004**, *16*, 279–285. [[CrossRef](#)] [[PubMed](#)]
132. Silva, B.; Pereira, J.A.; Cravo, S.; Araújo, A.M.; Fernandes, C.; Pinto, M.M.M.; De Pinho, P.G.; Remião, F. Multi-milligram resolution and determination of absolute configuration of pentedrone and methylone enantiomers. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2018**, *1100–1101*, 158–164. [[CrossRef](#)] [[PubMed](#)]
133. Pinto, M.M.M.; Fernandes, C.; Tiritan, M.E. Chiral Separations in Preparative Scale: A Medicinal Chemistry Point of View. *Molecules* **2020**, *25*, 1931. [[CrossRef](#)] [[PubMed](#)]
134. Sousa, M.E.; Tiritan, M.E.; Belaz, K.R.A.; Pedro, M.; Nascimento, M.S.J.; Cass, Q.B.; Pinto, M.M.M. Multimilligram enantioresolution of low-solubility xanthonolignoids on polysaccharide chiral stationary phases using a solid-phase injection system. *J. Chromatogr. A* **2006**, *1120*, 75–81. [[CrossRef](#)] [[PubMed](#)]
135. Fernandes, C.; Masawang, K.; Tiritan, M.E.; Sousa, E.; De Lima, V.; Afonso, C.; Bousbaa, H.; Sudprasert, W.; Pedro, M.; Pinto, M.M. New chiral derivatives of xanthenes: Synthesis and investigation of enantioselectivity as inhibitors of growth of human tumor cell lines. *Bioorg. Med. Chem.* **2014**, *22*, 1049–1062. [[CrossRef](#)] [[PubMed](#)]
136. Carraro, M.L.; Marques, S.; Silva, A.S.; Freitas, B.; Silva, P.M.A.; Pedrosa, J.; De Marco, P.; Bousbaa, H.; Fernandes, C.; Tiritan, M.E.; et al. Synthesis of New Chiral Derivatives of Xanthenes with Enantioselective Effect on Tumor Cell Growth and DNA Crosslinking. *ChemistrySelect* **2020**, *5*, 10285–10291. [[CrossRef](#)]
137. Fernandes, C.; Oliveira, L.; Tiritan, M.E.; Leitao, L.; Pozzi, A.; Noronha-Matos, J.B.; Correia-de-Sa, P.; Pinto, M.M. Synthesis of new chiral xanthone derivatives acting as nerve conduction blockers in the rat sciatic nerve. *Eur. J. Med. Chem.* **2012**, *55*, 1–11. [[CrossRef](#)]
138. Ribeiro, J.; Veloso, C.; Fernandes, C.; Tiritan, M.E.; Pinto, M.M.M. Carboxyxanthenes: Bioactive agents and molecular scaffold for synthesis of analogues and derivatives. *Molecules* **2019**, *24*, 180. [[CrossRef](#)]
139. Twibanire, J.-d.K.; Grindley, T.B. Efficient and Controllably Selective Preparation of Esters Using Uronium-Based Coupling Agents. *Org. Lett.* **2011**, *13*, 2988–2991. [[CrossRef](#)]
140. Fernandes, C.; Palmeira, A.; Ramos, I.I.; Carneiro, C.; Afonso, C.; Tiritan, M.E.; Cidade, H.; Pinto, P.C.A.G.; Saraiva, M.L.M.F.S.; Reis, S.; et al. Chiral derivatives of xanthenes: Investigation of the effect of enantioselectivity on inhibition of cyclooxygenases (COX-1 and COX-2) and binding interaction with human serum albumin. *Pharmaceuticals* **2017**, *10*, 50. [[CrossRef](#)]
141. Santos, Á.; Soares, J.X.; Cravo, S.; Tiritan, M.E.; Reis, S.; Afonso, C.; Fernandes, C.; Pinto, M.M.M. Lipophilicity assessment in drug discovery: Experimental and theoretical methods applied to xanthone derivatives. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2018**, *1072*, 182–192. [[CrossRef](#)] [[PubMed](#)]
142. Fernandes, C.; Palmeira, A.; Santos, A.; Tiritan, M.E.; Afonso, C.; Pinto, M.M. Enantioresolution of Chiral Derivatives of Xanthenes on (S,S)-Whelk-O1 and l-Phenylglycine Stationary Phases and Chiral Recognition Mechanism by Docking Approach for (S,S)-Whelk-O1. *Chirality* **2013**, *25*, 89–100. [[CrossRef](#)] [[PubMed](#)]

143. Carraro, M.L.; Palmeira, A.; Tiritan, M.E.; Fernandes, C.; Pinto, M.M.M. Resolution, determination of enantiomeric purity and chiral recognition mechanism of new xanthone derivatives on (S,S)-whelk-O1 stationary phase. *Chirality* **2017**, *29*, 247–256. [[CrossRef](#)] [[PubMed](#)]
144. Fernandes, C.; Tiritan, M.E.; Cass, Q.; Kairys, V.; Fernandes, M.X.; Pinto, M. Enantioseparation and chiral recognition mechanism of new chiral derivatives of xanthenes on macrocyclic antibiotic stationary phases. *J. Chromatogr. A* **2012**, *1241*, 60–68. [[CrossRef](#)] [[PubMed](#)]
145. Phyo, Y.Z.; Cravo, S.; Palmeira, A.; Tiritan, M.E.; Kijjoa, A.; Pinto, M.M.M.; Fernandes, C. Enantiomeric Resolution and Docking Studies of Chiral Xanthonic Derivatives on Chirobiotic Columns. *Molecules* **2018**, *23*, 142. [[CrossRef](#)] [[PubMed](#)]
146. Do Carmo, J.P.; Phyo, Y.Z.; Palmeira, A.; Tiritan, M.E.; Afonso, C.; Kijjoa, A.; M Pinto, M.M.; Fernandes, C. Enantioseparation, recognition mechanisms and binding of xanthenes on human serum albumin by liquid chromatography. *Bioanalysis* **2019**, *11*, 1255–1274. [[CrossRef](#)]
147. Pinto, M.; Tiritan, M.E.; Fernandes, C.; Cass, Q. Fases Estacionárias Quirais baseadas em Derivados Xantônicos. WO/2011/010284A2, 27 January 2011.
148. Fernandes, C.; Tiritan, M.E.; Pinto, M. Small Molecules as Chromatographic Tools for HPLC Enantiomeric Resolution: Pirkle-Type Chiral Stationary Phases Evolution. *Chromatographia* **2013**, *76*, 871–897. [[CrossRef](#)]
149. Corbett, T.H.; Panchapor, C.; Polin, L.; Lowichik, N.; Pugh, S.; White, K.; Kushner, J.; Meyer, J.; Czarniecki, J.; Chinnukroh, S.; et al. Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. *Investig. New Drugs* **1999**, *17*, 17–27. [[CrossRef](#)]
150. Stevenson, J.P.; DeMaria, D.; Reilly, D.; Purvis, J.D.; Graham, M.A.; Lockwood, G.; Drozd, M.; O'Dwyer, P.J. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. *Cancer Chemother. Pharmacol.* **1999**, *44*, 228–234. [[CrossRef](#)]
151. Pica-Mattoccia, L.; Cioli, D. Studies on the Mode of Action of Oxamniquine and Related Schistosomicidal Drugs. *Am. J. Trop. Med. Hyg.* **1985**, *34*, 112–118. [[CrossRef](#)]
152. Rosi, D.; Peruzzotti, G.; Dennis, E.W.; Berberian, D.A.; Freele, H.; Tullar, B.F.; Archer, S. Hycanthonone, 1 a New Active Metabolite of Lucanthonone 2. *J. Med. Chem.* **1967**, *10*, 867–876. [[CrossRef](#)] [[PubMed](#)]
153. Naidu, M.D.; Agarwal, R.; Pena, L.A.; Cunha, L.; Mezei, M.; Shen, M.; Wilson, D.M., III; Liu, Y.; Sanchez, Z.; Chaudhary, P.; et al. Lucanthonone and Its Derivative Hycanthonone Inhibit Apurinic Endonuclease-1 (APE1) by Direct Protein Binding. *PLoS ONE* **2011**, *6*, e23679. [[CrossRef](#)] [[PubMed](#)]
154. Cioli, D.; Pica-Mattoccia, L.; Archer, S. Antischistosomal drugs: Past, present . . . and future? *Pharmacol. Ther.* **1995**, *68*, 35–85. [[CrossRef](#)]
155. Ong, T.m.; De Serres, F.J. Mutagenic evaluation of antischistosomal drugs and their derivatives in *Neurospora crassa*. *J. Toxicol. Environ. Health* **1975**, *1*, 271–279. [[CrossRef](#)] [[PubMed](#)]
156. LoRusso, P.M.; Foster, B.J.; Wozniak, A.; Heilbrun, L.K.; McCormick, J.I.; Ruble, P.E.; Graham, M.A.; Purvis, J.; Rake, J.; Drozd, M.; et al. Phase I Pharmacokinetic Study of the Novel Antitumor Agent SR233377. *Clin. Cancer Res.* **2000**, *6*, 3088–3094. [[PubMed](#)]
157. Goncalves, P.H.; High, F.; Juniewicz, P.; Shackleton, G.; Li, J.; Boerner, S.; LoRusso, P.M. Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies. *Investig. New Drugs* **2008**, *26*, 347–354. [[CrossRef](#)]
158. Lockhart, A.C.; Calvo, E.; Tolcher, A.W.; Rowinsky, E.K.; Shackleton, G.; Morrison, J.G.; Rafi, R.; VerMeulen, W.; Rothenberg, M.L. A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors. *Am. J. Clin. Oncol.* **2009**, *32*, 9–14. [[CrossRef](#)]
159. Soria, J.-C.; Dieras, V.; Girre, V.; Yovine, A.; Mialaret, K.; Armand, J.-P. QTc Monitoring During a Phase I Study: Experience With SR271425. *Am. J. Clin. Oncol.* **2007**, *30*, 106–112. [[CrossRef](#)]
160. Mansoori, B.; Mohammadi, A.; Davudian, S.; Shirjang, S.; Baradaran, B. The Different Mechanisms of Cancer Drug Resistance: A Brief Review. *Adv. Pharm. Bull.* **2017**, *7*, 339–348. [[CrossRef](#)]
161. Kim, Y.; Chen, J. Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation. *Science* **2018**, *359*, 915–919. [[CrossRef](#)]
162. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-glycoprotein: From genomics to mechanism. *Oncogene* **2003**, *22*, 7468–7485. [[CrossRef](#)] [[PubMed](#)]
163. Palmeira, A.; Sousa, E.; Helena Vasconcelos, M.; Pinto, M.; Fernandes, M.X. Structure and Ligand-based design of P-glycoprotein inhibitors: A historical perspective. *Curr. Pharm. Des.* **2012**, *18*, 4197–4214. [[CrossRef](#)] [[PubMed](#)]
164. McDevitt, C.A.; Callaghan, R. How can we best use structural information on P-glycoprotein to design inhibitors? *Pharmacol. Ther.* **2007**, *113*, 429–441. [[CrossRef](#)] [[PubMed](#)]
165. Wang, R.B.; Kuo, C.L.; Lien, L.L.; Lien, E.J. Structure–activity relationship: Analyses of p-glycoprotein substrates and inhibitors. *J. Clin. Pharm. Ther.* **2003**, *28*, 203–228. [[CrossRef](#)] [[PubMed](#)]
166. Palmeira, A.; Sousa, E.; Vasconcelos, M.H.; Pinto, M.M. Three decades of P-gp Inhibitors: Skimming through several generations and scaffolds. *Curr. Med. Chem.* **2012**, *19*, 1946–2025. [[CrossRef](#)]
167. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. *Drug Discov. Today* **2004**, *9*, 641–651. [[CrossRef](#)]
168. Richard, M.; Zoran, R. Designing Multiple Ligands—Medicinal Chemistry Strategies and Challenges. *Curr. Pharm. Des.* **2009**, *15*, 587–600. [[CrossRef](#)]

169. Ramsay, R.R.; Popovic-Nikolic, M.R.; Nikolic, K.; Uliassi, E.; Bolognesi, M.L. A perspective on multi-target drug discovery and design for complex diseases. *Clin. Transl. Med.* **2018**, *7*, 3. [CrossRef]
170. Palmeira, A.; Vasconcelos, M.H.; Paiva, A.; Fernandes, M.X.; Pinto, M.; Sousa, E. Dual inhibitors of P-glycoprotein and tumor cell growth: (Re)discovering thioxanthenes. *Biochem. Pharmacol.* **2012**, *83*, 57–68. [CrossRef]
171. Palmeira, A.; Rodrigues, F.; Sousa, E.; Pinto, M.; Vasconcelos, M.H.; Fernandes, M.X. New Uses for Old Drugs: Pharmacophore-Based Screening for the Discovery of P-Glycoprotein Inhibitors. *Chem. Biol. Drug Des.* **2011**, *78*, 57–72. [CrossRef]
172. Garrigos, M.; Mir, L.M.; Orłowski, S. Competitive and Non-Competitive Inhibition of the Multidrug-Resistance-Associated P-glycoprotein ATPase. *Eur. J. Biochem.* **1997**, *244*, 664–673. [CrossRef] [PubMed]
173. Litman, T.; Zeuthen, T.; Skovsgaard, T.; Stein, W.D. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. *Biochim. Biophys. Acta (BBA) Mol. Basis Dis.* **1997**, *1361*, 169–176. [CrossRef]
174. Silva, R.; Carmo, H.; Vilas-Boas, V.; Barbosa, D.J.; Palmeira, A.; Sousa, E.; Carvalho, F.; Bastos, M.d.L.; Remião, F. Colchicine effect on P-glycoprotein expression and activity: In silico and in vitro studies. *Chem. Biol. Interact.* **2014**, *218*, 50–62. [CrossRef] [PubMed]
175. Barbosa, J.; Lima, R.T.; Sousa, D.; Gomes, A.S.; Palmeira, A.; Seca, H.; Choosang, K.; Pakkong, P.; Bousbaa, H.; Pinto, M.M.; et al. Screening a small library of xanthenes for antitumor activity and identification of a hit compound which induces apoptosis. *Molecules* **2016**, *21*, 81. [CrossRef] [PubMed]
176. Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM). Available online: <https://clinicaltrials.gov/ct2/show/NCT01587144> (accessed on 25 November 2020).
177. Lima, R.T.; Sousa, D.; Paiva, A.M.; Palmeira, A.; Barbosa, J.; Pedro, M.; Pinto, M.M.; Sousa, E.; Vasconcelos, M.H. Modulation of autophagy by a thioxanthone decreases the viability of melanoma cells. *Molecules* **2016**, *21*, 1343. [CrossRef] [PubMed]
178. Lima, R.T.; Sousa, D.; Gomes, A.S.; Mendes, N.; Matthiesen, R.; Pedro, M.; Marques, F.; Pinto, M.M.; Sousa, E.; Helena Vasconcelos, M. The antitumor activity of a lead thioxanthone is associated with alterations in cholesterol localization. *Molecules* **2018**, *23*, 3301. [CrossRef]
179. Palmeira, A.; Sousa, E.; Fernandes, M.X.; Pinto, M.M.; Helena Vasconcelos, M. Multidrug resistance reversal effects of aminated thioxanthenes and interaction with cytochrome P450 3A4. *J. Pharm. Pharm. Sci.* **2011**, *15*, 31–45. [CrossRef]
180. Kannan, P.; Telu, S.; Shukla, S.; Ambudkar, S.V.; Pike, V.W.; Halldin, C.; Gottesman, M.M.; Innis, R.B.; Hall, M.D. The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2). *ACS Chem. Neurosci.* **2011**, *2*, 82–89. [CrossRef]
181. Lopes, A.; Martins, E.; Silva, R.; Pinto, M.M.M.; Remião, F.; Sousa, E.; Fernandes, C. Chiral Thioxanthenes as Modulators of P-glycoprotein: Synthesis and Enantioselectivity Studies. *Molecules* **2018**, *23*, 626. [CrossRef]
182. Silva, R.; Vilas-Boas, V.; Carmo, H.; Dinis-Oliveira, R.J.; Carvalho, F.; De Lourdes Bastos, M.; Remião, F. Modulation of P-glycoprotein efflux pump: Induction and activation as a therapeutic strategy. *Pharmacol. Ther.* **2015**, *149*, 1–123. [CrossRef]
183. Maglich, J.M.; Stoltz, C.M.; Goodwin, B.; Hawkins-Brown, D.; Moore, J.T.; Kliewer, S.A. Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Regulate Overlapping but Distinct Sets of Genes Involved in Xenobiotic Detoxification. *Mol. Pharmacol.* **2002**, *62*, 638–646. [CrossRef] [PubMed]
184. Silva, R.; Palmeira, A.; Carmo, H.; Barbosa, D.J.; Gameiro, M.; Gomes, A.; Paiva, A.M.; Sousa, E.; Pinto, M.; Bastos, M.L.; et al. P-glycoprotein induction in Caco-2 cells by newly synthesized thioxanthenes prevents paraquat cytotoxicity. *Arch. Toxicol.* **2015**, *89*, 1783–1800. [CrossRef] [PubMed]
185. Ferreira, A.F.; Ponte, F.; Silva, R.; Rocha-Pereira, C.; Sousa, E.; Pinto, M.; Bastos, M.D.L.; Remião, F. Quantification of 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5), a newly synthesized P-glycoprotein inducer/activator, in biological samples: Method development and validation. *Biomed. Chromatogr.* **2017**, *31*. [CrossRef] [PubMed]
186. Silva, V.; Gil-Martins, E.; Silva, B.; Rocha-Pereira, C.; Sousa, M.E.; Remião, F.; Silva, R. Xanthenes as P-glycoprotein modulators and their impact on drug bioavailability. *Expert Opin. Drug Metab. Toxicol.* **2020**. [CrossRef]